Dexcom (DXCM) 10-K risk factor changes: FY2024 vs FY2023
The 2024-12-31 10-K against the 2023-12-31 one, compared heading by heading and sentence by sentence.
Item 1A167 rewritten56 added62 removed921 unchanged
All filing items986 rewritten303 added267 removed2,461 unchanged
Summary
counted, not written
- Item 1A lists 74 risk factor headings: 0 new, 8 reworded and 66 unchanged since FY2023. 3 headings from FY2023 no longer appear.
- Sentence by sentence, 303 added, 267 removed, 986 rewritten and 2,461 unchanged across 18 items that differ.
New Item 1A headings (0)
No risk factor heading in this filing is absent from FY2023.
Removed Item 1A headings (3)
- We are subject to cost-containment efforts by third-party payors that could result in reduced product pricing and/or sales of our products and cause a reduction in revenue.
- Our CGM systems currently have regulatory marketing authorization limited to individual patient home-use, and have otherwise not received clearance or approval from the FDA or other regulators for use in hospital or other in-patient facility settings, although the FDA has advised us that it will not object to the use of our CGM systems in such settings during the COVID-19 pandemic. Our potential supply of our CGM systems for use in this environment during the COVID-19 pandemic may present risks to our business.
- The warrants related to the 2023 Notes and our common stock.
Reworded Item 1A headings (8)
- If we are unable to establish and maintain adequate sales, marketing and distribution capabilities
[removed: or][added: and/or] enter into and maintain arrangements with third parties to sell, market and distribute our products, we may have difficulty achieving market awareness and selling our products in the future. - Failure to obtain any required regulatory authorization in
[removed: foreign][added: international] jurisdictions will prevent us from marketing our products abroad. - We are subject to complex and evolving U.S. and
[removed: foreign][added: international] laws and regulations and other requirements regarding privacy, data protection, security, and other matters. Many of these laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, monetary penalties, increased cost of operations, or declines in user growth or engagement, or otherwise harm our business. - We
[removed: are][added: may be] subject to claims of infringement or misappropriation of the intellectual property rights of others, which could prohibit us from shipping affected products, require us to obtain licenses from third parties or to develop non-infringing alternatives, and subject us to substantial monetary damages and injunctive relief. We may also be subject to other claims or suits. - We may conduct additional financings to continue the development or commercialization of our current or future
[removed: generation CGM systems.][added: products.] - Our [added: Amended] Credit
[removed: Facility][added: Agreement] imposes restrictions on us that may adversely affect our ability to operate our business. [removed: Environmental,][added: Sustainability (including environmental,] social and[removed: governance, or ESG,][added: governance)] regulations, policies and provisions could expose us to numerous risks.- Our business could be negatively impacted by evolving expectations and challenges relating to implementing
[removed: ESG][added: sustainability (including environmental, social and governance)] initiatives, setting[removed: ESG-related][added: sustainability-related] goals, collecting[removed: ESG-related][added: sustainability-related] data, and disclosing[removed: ESG-related][added: sustainability-related] information.
A heading is new when no FY2023 heading matches it after ignoring case and punctuation, and reworded when it shares at least 60 percent of its words with one that went away. All current risk factor headings.
Sentences by item
24 items, with every count and a link to each item that changed
Underlined words on a shaded ground are new in FY2024; struck-through words were in FY2023. Sentences that are wholly new or wholly gone are labelled rather than marked.
Item 1A. RISK FACTORS
167 rewritten, 56 added, 62 removed, 921 unchanged
Read the full itemFY2024 item · filed February 18, 2025FY2023 item · filed February 8, 2024
We have experienced, and anticipate that we will continue to experience, decreasing prices for our products due to pricing pressure from managed care organizations and other third-party [removed: payors, increased market power of payors, and increased competition among suppliers, including manufacturing services providers, as the medical device industry consolidates.][added: payors.]
If the prices for our products [removed: and services] decrease [removed: and] [added: and/or if] we are unable to [removed: reduce our expenses, including] [added: offset] the [removed: cost] [added: effects] of [removed: sourcing materials, logistics and] [added: general inflation on our operating costs through increases in] the [removed: cost to manufacture] [added: prices for] our products, our business, results of operations, financial condition and cash flows will be adversely affected.
Most of our customers rely on third-party payors, including government programs and private health insurance plans, to cover the cost of [removed: our products.][added: the G6, G7 and Dexcom One.]
We expect that these continuing cost reduction and containment measures [removed: may reduce the cost or utilization of our] [added: could result in lower prices for these] products and [added: lower reimbursement rates, as well as] could lead to patients being unable to obtain approval for coverage or payment from these third-party payors [removed: or to] [added: resulting in] costs being shifted to patients for [removed: our] [added: these] products.
Therefore, Medicare reimbursement for our CGM devices is subject to various coverage conditions [added: and often requires a patient-specific coverage analysis.]
As of December 31, [removed: 2023,] [added: 2024,] the eight largest private third-party [removed: payors,] [added: payors] in [added: the United States, in] terms of the number of covered lives, have issued coverage policies for the category of CGM devices.
In addition, we have negotiated contracted rates with all of those third-party payors for the purchase of [removed: our current CGM] [added: the G6 and G7] systems by their members.
In addition, in the United States, [removed: people with diabetes using] existing single-point finger stick devices [added: used by people with diabetes] are generally [removed: reimbursed] [added: reimbursable for] all or part of the product cost by Medicare or other third-party payors, which may be perceived as more advantageous for consumers.
Further, while many third-party payors have adopted some form of coverage policy on CGM devices, in a sizeable percentage of cases, under durable medical equipment benefits, those coverage policies frequently are restrictive and require significant medical documentation and other requirements in order [removed: for policy holders] to obtain reimbursement, and as a result, we have difficulty improving the efficiency of our customer service group.
This final rule [removed: expands] [added: expanded] coverage of CGMs to include [removed: a large competitor’s] competing [removed: device,] [added: devices,] which may [removed: negatively] [added: continue to have a negative] impact [added: on] our [removed: sales.][added: sales as a result of increased market competition.]
Furthermore, payors are increasingly basing reimbursement rates on factors such as prior approvals and the effectiveness of the product, clinical outcomes associated with the product, and any factors that [added: negatively impact the effectiveness or clinical outcomes (or cause a perception of any such negative impact), such as the results of a clinical trial, a product defect, or a product recall, which could negatively impact the reimbursement rate.]
[removed: Also, the trends toward managed healthcare in the United States and legislative efforts intended to reduce the cost of] government insurance programs could significantly influence the purchase of healthcare services and products and may result in lower prices for our products or the exclusion of our products from reimbursement programs.
In many [removed: foreign] [added: international] markets, pricing and profitability of medical devices are subject to government control.
In the United States, [removed: we expect that there will continue to be] federal and state proposals for similar [removed: controls.][added: controls may continue and/or increase.]
The development of new products, or novel technologies and services and the enhancement of our current CGM products (including seeking and potentially obtaining new indications for use), [added: is difficult, expensive and time-consuming and] requires significant investment in research and development, intellectual property protection, clinical trials, regulatory approvals and in obtaining third party reimbursement.
Even if a product receives marketing authorization from the FDA or comparable international regulator, it may not be accepted in the marketplace by health care [removed: professionals and] [added: professionals,] people with [removed: diabetes.][added: diabetes and those seeking to optimize metabolic health.]
Any factors that may limit our partners’ ability to achieve widespread adoption of their systems, including competitive pressures, technological breakthroughs for the treatment or prevention of diabetes, adverse regulatory or legal actions relating to insulin pump products, or [added: changes in reimbursement rates or policies of third-party payors relating to insulin pumps or similar products, could have an adverse impact on our operating results.]
[removed: In the event of such a termination, we may be required to devote] additional resources to product development and commercialization, we may need to cancel some development programs and we may face increased competition.
- widespread market acceptance of our products by health care [removed: professionals and] [added: professionals,] people with diabetes [added: and those seeking to optimize metabolic health] will largely depend on our ability to demonstrate their relative safety, effectiveness, reliability, cost-effectiveness and ease of use;
In addition to the risks outlined above, our [removed: G6] [added: G6, G7, Dexcom One,] and [removed: G7] [added: Stelo] systems are more invasive than many other self-monitored glucose testing systems, including single-point finger stick devices, and people with diabetes [added: and those seeking to optimize metabolic health] may be unwilling to insert a sensor in their body, especially [added: for those with diabetes] if their current diabetes management involves no more than two finger sticks per day.
[removed: Moreover,] people with diabetes [added: and those seeking to optimize metabolic health] may not perceive the benefits of CGM and [added: people with diabetes] may be unwilling to change their current treatment regimens.
Health care professionals may not recommend or prescribe our products unless and until (i) there is more long-term clinical evidence to convince them to alter their existing treatment methods, (ii) there are additional recommendations from prominent physicians that our products are effective in monitoring glucose levels, [removed: and] (iii) reimbursement or insurance coverage is more widely [removed: available.][added: available, and (iv) patient out of pocket cost decreases.]
In addition, market acceptance of our products [added: internationally] by [removed: physicians] [added: health care professionals] and people with diabetes [removed: in Europe or other countries] [added: and those seeking to optimize metabolic health] will largely depend on our ability to demonstrate their relative safety, effectiveness, reliability, cost-effectiveness and ease of use.
If we are unable to do so, we may not be able to generate product revenue from our [added: international] sales [removed: efforts in Europe or other countries.][added: efforts.]
We cannot predict when, if ever, healthcare professionals, including physicians, and people with diabetes [added: and those seeking to optimize metabolic health] may adopt more widespread use of CGM systems, including our systems.
If our CGM systems do not achieve and maintain an adequate level of acceptance by people with diabetes, [added: those seeking to optimize metabolic health,] healthcare professionals, including physicians, and third party payors, our future revenue may be reduced and our business may be harmed.
From time to time, we have also experienced [removed: brief] periods of backorder [added: where we have had insufficient supply of our product] and, at times, have had to limit the efforts of our sales force to introduce our products to new customers.
[removed: We] [added: Moreover, we] may not adequately predict the market demand for our products, [removed: in order] [added: which may lead us] to produce our products in the quantities we anticipate will be necessary to meet [added: actual] market demand.
We will need to adequately predict the market demand for our [removed: products] [added: products, remedy our recent manufacturing challenges,] and increase our manufacturing capacity by a significant factor over the current level to meet or exceed the anticipated market demand by product.
We [removed: are] also [removed: expanding our facility in Mesa, Arizona, and plan to begin] [added: commenced] construction of a new facility in Ireland to scale up manufacturing capacity.
[removed: The scaling of] [added: Our ability to scale] manufacturing capacity is subject to numerous risks and uncertainties, and may lead to variability in product quality or reliability, increased construction timelines, as well as resources required to design, [removed: install and maintain manufacturing equipment, among others, all of which can lead to unexpected delays in manufacturing output.]
Our facilities are subject to inspections by the FDA and corresponding state and international agencies on an ongoing basis, and we must comply with Good Manufacturing Practices and the FDA Quality System Regulation, as well as certain state [added: and local requirements.]
We may be unable to adequately maintain, develop and expand our manufacturing process and operations or maintain compliance with FDA and state and international agency [removed: requirements, and manufacturing issues could impact our cleared and approved products.][added: requirements.]
If we are unable to manufacture a sufficient supply of our current products or any future products for which we may receive approval or clearance, maintain control over expenses or otherwise adapt to anticipated growth, or if we underestimate growth, we may not have the capability to satisfy market [removed: demand,] [added: demand or our] contractual obligations, and our business will suffer.
[removed: Our] [added: In addition, our] products are manufactured at certain facilities, with limited alternate facilities.
Wildfires are also increasingly [removed: more] common in southern California and present risk to our manufacturing operations.
If we experience manufacturing difficulties or disruptions, [added: or if we fail to remedy our recent manufacturing and inventory challenges,] it could result in insufficient inventory, increased costs, immediate shortages in product or component supply, and decreased sales, [removed: and] [added: any of which may harm] our [removed: business could be harmed.][added: business.]
In some cases, our agreements with these and other suppliers can be terminated by [removed: either party upon short notice.]
Our manufacturers and suppliers may also experience or be impacted by equipment malfunction, environmental factors, [added: cyber-attacks] and public health emergencies, any of which could delay or impede their ability to meet our demand.
[added: If there are regulatory delays or impediments impacting] our suppliers or us for any reason, we may not be able to quickly establish additional or replacement suppliers, particularly for our single-source components, in part because of the custom nature of various parts we design.
In addition to decreased pricing, we may be unable to reduce our expenses, including the cost of sourcing materials, logistics and the cost to manufacture our products.
In addition, 2025 will bring a new presidential administration, which may shift health policy priorities, including potential impacts on Medicare coverage and reimbursement.
Also, the trends toward managed healthcare in the United States, which we expect to continue in 2025 and beyond, and legislative efforts intended to reduce the cost of
In the event of such a termination, we may be required to devote
Moreover,
We have recently experienced manufacturing and inventory challenges for G7 that have resulted, and may continue to result from time to time, in disruptions in our ability to supply certain markets, including in the U.S. and other countries.
While we are currently working to remedy such challenges, we cannot predict when such manufacturing and inventory challenges will be remedied.
If we fail to produce a sufficient amount of our products, our ability to supply our markets will be compromised and health care providers and people with diabetes’ decisions to use our products may be negatively impacted.
This could lead to loss of sales of and revenues from our products, could potentially decrease our market share, and/or our business, financial condition, results of operations and growth prospects could be materially adversely affected.
install and maintain manufacturing equipment, among others, all of which can lead to unexpected delays in manufacturing output.
Our products require multiple manufacturing processes and steps.
Problems with these manufacturing processes, which may not be detectable by us in a timely manner, could lead to product defects or manufacturing failures, resulting in lot failures, product recalls, product liability claims and/or insufficient inventory, any of which could negatively impact our sales.
As further described in the risk factor above, we have recently experienced manufacturing and inventory challenges that have resulted, and may continue to result from time to time, in disruptions in our ability to supply certain markets, including in the U.S. and other countries.
either party upon short notice.
In 2024, we launched Stelo in the United States and are expanding distribution capabilities for its sales.
In selling Stelo, we compete directly with the Diabetes Care division of Abbott Laboratories.
We are also aware of emerging competitors primarily located in China.
We also are building a new manufacturing facility in Ireland.
- fluctuations in trade policy and tariff regulations, including potential higher tariffs on imported goods and materials and renegotiation of free trade agreements and potential retaliatory tariffs imposed by foreign countries against U.S. goods; and
contracting, and could disrupt our business, and result in a material adverse effect on our business, financial condition, and results of operations.
May 2018.
including sales, billing, customer service, procurement and supply chain, manufacturing, and distribution.
such laws, and potentially be awarded a share of any damages or penalties ultimately awarded to the applicable government body.
As part of our commitment to technological advancement, we have incorporated and will continue to explore and implement AI-enabled functions into our products and services.
We continue to explore how best to leverage and harness the efficiency and innovation of AI-enabled and AI-empowered technology.
In our deployment of AI, we strive to continually assess its performance and continue to make improvements.
AI laws and regulations have proliferated in the U.S. and globally in recent years, including in 2024.
In 2024, there were 60 AI-related regulations at the U.S. federal and state levels, up from just one in 2016.
In 2024 alone, the total number of AI-related regulations in the U.S. grew by 140%.
On January 10, 2025, HHS released its AI Strategic Plan which largely focuses on promoting trustworthy AI through the FAVES framework (Fair, Appropriate, Valid, Effective, Safe).
Additionally, the EU AI Act went into effect on August 1, 2024, which sets requirements for developers and deployers of AI systems based on a risk approach and extends its reach to those developers of AI outside of the EU where the AI product or output is used in the EU.
AI regulation is continually evolving at the federal, state and international level and will continue to require financial and resource investment by us to ensure that AI tools are safe and effective, operate in a non-discriminatory manner, and comply with applicable legal and regulatory requirements.
In 2024, the FDA cleared Stelo as an over-the-counter biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin.
The uncertain timing of regulatory approvals for future generations of our products could subject our current
As 2025 ushers in a new presidential administration, we expect material changes in health policy, enforcement initiatives, and coverage and reimbursement for health care items and services.
As such, our costs to monitor these changes and respond to new requirements will increase.
These include changes that may reduce
Adverse determinations in a judicial or administrative proceeding or failure to obtain necessary intellectual property
The loss of the services of members of our senior management, scientists, clinicians or engineers could prevent the implementation and completion of our
Additionally, in June 2024, the State of California enacted S.B. 167, which suspends the use of NOLs for the tax period from January 1, 2024 to December 31, 2026 for net business income of $1.0 million or more, as well as limits the utilization of research and development tax credits to $5.0 million each year.
We are subject to cost-containment efforts by third-party payors that could result in reduced product pricing and/or sales of our products and cause a reduction in revenue.
Additionally, as a result of the economic slowdown, some customers have lost access and others may lose access to their private health insurance plan if they lose their job, and an impact to job status may extend for a prolonged period of time, beyond possible coverage periods through COBRA, or where the cost to maintain coverage may not be affordable to our customers.
As most of our customers currently rely on third-party payors, including government programs and private health insurance plans, to cover the cost of our products, our customers may lose coverage or reimbursement for our products, which may harm our business and results of operations.
We have experienced, and anticipate that we will continue to experience, downward pressure on product pricing.
and often requires a patient-specific coverage analysis.
negatively impact the effectiveness or clinical outcomes (or cause a perception of any such negative impact), such as the results of a clinical trial, a product defect, or a product recall, which could negatively impact the reimbursement rate.
changes in reimbursement rates or policies of third-party payors relating to insulin pumps or similar products, could have an adverse impact on our operating results.
We have focused significant effort on continual improvement programs in our manufacturing operations intended to improve quality, yields and throughput.
We have made progress in manufacturing to enable us to supply adequate amounts of product to support our commercialization efforts; however, we cannot guarantee that supply will not be constrained in the future.
requirements.
If there are regulatory delays or impediments impacting
device market.
We also and plan to begin construction of a new facility in Ireland.
- fluctuations in trade policy and tariff regulations; and
instances, non-U.S. persons, in conducting activities, and transacting business with or making investments in certain countries, governments, entities and individuals subject to U.S. economic sanctions.
which will arise in the ordinary course of business and may increase in frequency as we continue to grow and expand our operations.
For example, the Federal Trade Commission uses its consumer
curtailment of our operations.
market these CGM systems in the United States or outside of the United States.
Our CGM systems currently have regulatory marketing authorization limited to individual patient home-use, and have otherwise not received clearance or approval from the FDA or other regulators for use in hospital or other in-patient facility settings, although the FDA has advised us that it will not object to the use of our CGM systems in such settings during the COVID-19 pandemic.
Our potential supply of our CGM systems for use in this environment during the COVID-19 pandemic may present risks to our business.
We have received, and may continue to receive, numerous inquiries from hospitals around the country about the use of our CGM devices to remotely monitor COVID-19 patients admitted into the hospital.
Following direct communication with the FDA regarding the potential use of our CGM devices in a hospital or other in-patient setting, the FDA notified us on April 1, 2020 that in an exercise of its enforcement discretion it will not object, in the context of the COVID-19 pandemic, to Dexcom providing CGM devices and support to users to enable real-time remote patient monitoring in hospitals and other healthcare facilities, to support COVID-19 healthcare-related efforts, so long as we provide certain FDA-specified information with respect to the unique challenges that CGM technologies can raise in the hospital environment.
As a condition of its exercise of enforcement discretion, the FDA has advised that we communicate the following information related to implementing the use of CGM systems for remote monitoring of hospitalized patients:
- Hospitals should consider whether they have the resources and expertise necessary to adequately implement CGM use and provide appropriate training to healthcare providers.
- CGM glucose results are less accurate than blood glucose results obtained using traditional testing methods (e.g., lab glucose, blood glucose meters).
Users should consider all CGM glucose information (e.g., trend) along with individual glucose values, and interpret CGM results in the context of the full clinical picture.
- CGM systems are subject to interferences that may generate falsely high and falsely low glucose readings.
Levels of interference depend on drug concentration; substances that may not significantly interfere in non-hospitalized patients may interfere when used in the hospital setting because of higher dose levels.
Most drugs used in hospital or critical care settings have not been evaluated and their interference with CGM systems is unknown.
Known interferences vary by CGM brand, and can include Acetaminophen, Ascorbic acid, Hydroxyurea, or other reducing drugs/ compounds.
- Poor peripheral blood perfusion may cause inaccurate sensor readings.
CGM results should be interpreted considering accompanying patient conditions and medications.
Other clinical conditions may also cause inaccurate readings.
Our provision of our CGM systems to hospitals and other healthcare facilities for use have and will continue to have the above notice.
In February 2022, we received Breakthrough Device designation for our G6 CGM system in the hospital setting.
The FDA’s Breakthrough Device designation is designed to expedite the development and regulatory review of medical devices that hold the potential for more effective treatment or diagnosis of life-threatening or irreversibly debilitating disease or condition.
Given that our CGM devices have not yet been fully evaluated or tested by either us or the FDA to the extent that would be required in standard circumstances for product development and marketing authorization, there could be unknown or unanticipated risks presented by use in this environment.
The FDA can also decide, at any time, to change its position regarding its Breakthrough Device Designation and/or enforcement discretion for our devices, and require that we seek marketing authorization for this additional intended use by submitting a 510(k) premarket notification, or that we seek and obtain Emergency Use Authorization.
The COVID-19 public health emergency declared by the Department of Health and Human Services expired on May 11, 2023.
An excerpt. Shown here: 40 of 167 rewritten, 40 of 56 added and 40 of 62 removed. The counts are complete. For every sentence, read Item 1A. RISK FACTORS in the FY2024 filing and the FY2023 filing.
Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
77 rewritten, 21 added, 12 removed, 116 unchanged
Read the full itemFY2024 item · filed February 18, 2025FY2023 item · filed February 8, 2024
| | | | We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes [added: and metabolic health] by patients, caregivers, and clinicians around the world. We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation systems, the Dexcom [removed: G6*®*] [added: G6] integrated Continuous Glucose Monitoring System, or G6, in [removed: 2018] [added: 2018,] and [removed: more recently received marketing clearance from the FDA on] [added: we launched] the Dexcom [removed: G7®,] [added: G7,] or G7, in [removed: December 2022.] [added: 2023. In August 2024, we launched Stelo, our new biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin, as the first over-the-counter glucose biosensor in the U.S.] Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “Dexcom” refer to DexCom, Inc. and its subsidiaries. | | |
| | | | Partnerships: We also continue to pursue and support development partnerships with insulin pump companies and companies or institutions developing insulin delivery systems, including automated insulin delivery systems. [added: With the introduction of Stelo, we are also pursuing and supporting development partnerships with consumer technology product companies that seek to provide metabolic health insights to their customers.] | | |
| | | | New Opportunities: We are also exploring how to extend our offerings to other opportunities, including for people with [removed: Type 2 diabetes that are non-insulin using, people with] pre-diabetes, people who are obese, people who are pregnant, and people in the hospital setting. Eventually, we may apply our technological expertise to products beyond glucose monitoring. | | |
The discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which we have prepared in accordance with [removed: U.S.] GAAP.
While our significant accounting policies are described in Note 1 [removed: “Organization] [added: “*Organization] and Significant Accounting [removed: Policies”] [added: Policies*”] to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K, we believe that the following accounting estimates are most critical to a full understanding and evaluation of our reported financial results.
We estimate [removed: provisions for] pharmacy rebates based on contractual arrangements, estimates of products sold subject to rebate, known events or [removed: trends] [added: trends,] and channel inventory data.
Estimates associated with [removed: rebates on products sold through our distributors under] pharmacy [removed: benefits] [added: rebates] are the most significant component of our variable consideration estimates and most at risk for material adjustment because of the time delay between the recording of the [removed: provision] [added: pharmacy rebate] and its ultimate settlement, an interval that generally ranges from 30 to 90 days, but can last up to one year.
An increase or decrease of 1% in our estimate of products sold subject to rebate during [removed: 2023,] [added: 2024,] holding all other assumptions constant, would increase or decrease revenue by approximately [removed: $22.9] [added: $38.7] million.
For more information, see [removed: *Revenue Recognition* in] Note 1 [removed: “Organization] [added: “*Organization] and Significant Accounting [removed: Policies”] [added: Policies—Revenue Recognition*”] to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K.
We use the asset and liability approach to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities as described in Note 1 [removed: “Organization] [added: “*Organization] and Significant Accounting [removed: Policies”] [added: Policies—Income Taxes*”] to the consolidated financial statements in Part II, Item 8 of this Annual Report.
We maintain a valuation allowance on our California research and development tax [added: credits, foreign tax] credits and certain foreign intangible assets, as it is more likely than not that those deferred tax assets will not be realized.
We recognize and measure benefits for uncertain tax positions using a two-step approach as described in Note 1 [removed: “Organization] [added: “*Organization] and Significant Accounting [removed: Policies”] [added: Policies—Income Taxes*”] to the consolidated financial statements in Part II, Item 8 of this Annual Report.
| Key Highlights for fiscal [removed: 2023] [added: 2024] include the following: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
We ended fiscal [removed: 2023] [added: 2024] with cash, cash equivalents and short-term marketable securities totaling [removed: $2.72] [added: $2.58] billion.
[removed: ][added: ]
For discussion related to the results of operations and changes in financial condition for fiscal [removed: 2022] [added: 2023] compared to fiscal [removed: 2021] [added: 2022] refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of our [removed: 2022] [added: 2023] Annual Report on Form 10-K, which was filed with the SEC on February [removed: 9, 2023.][added: 8, 2024.]
| Twelve Months Ended December 31, [removed: 2023] [added: 2024] Compared to Twelve Months Ended December 31, [removed: 2022] [added: 2023] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | Twelve Months Ended December 31, | | | | | | | | | | | | | | | | | | | | | | | | [removed: 2023] [added: 2024] - [removed: 2022] [added: 2023] | | | | | | | | |
| *(In millions, except per share amounts)* | | | [removed: 2023] [added: 2024] | | | | | | % of Revenue (1) | | | | | | [removed: 2022] [added: 2023] | | | | | | % of Revenue (1) | | | | | | $ Change | | | | | | % Change | | |
| Gross profit | | | [removed: 2,288.9] [added: 2,438.2] | | | | | | [removed: 63.2] [added: 60.5] | | % | | | | [removed: 1,883.1] [added: 2,288.9] | | | | | | [removed: 64.7] [added: 63.2] | | % | | | | [removed: 405.8] [added: 149.3] | | | | | | [removed: 22] [added: 7] | | % |
| Research and development | | | [removed: 505.8] [added: 552.4] | | | | | | 14 | | % | | | | [removed: 484.2] [added: 505.8] | | | | | | [removed: 17] [added: 14] | | % | | | | [removed: 21.6] [added: 46.6] | | | | | | [removed: 4] [added: 9] | | % |
| Selling, general and administrative | | | [removed: 1,185.4] [added: 1,285.8] | | | | | | [removed: 33] [added: 32] | | % | | | | [removed: 1,007.7] [added: 1,185.4] | | | | | | [removed: 35] [added: 33] | | % | | | | [removed: 177.7] [added: 100.4] | | | | | | [removed: 18] [added: 8] | | % |
| Total operating expenses | | | [removed: 1,691.2] [added: 1,838.2] | | | | | | [removed: 47] [added: 46] | | % | | | | [removed: 1,491.9] [added: 1,691.2] | | | | | | [removed: 51] [added: 47] | | % | | | | [removed: 199.3] [added: 147.0] | | | | | | [removed: 13] [added: 9] | | % |
| Operating income | | | [removed: 597.7] [added: 600.0] | | | | | | [removed: 17] [added: 15] | | % | | | | [removed: 391.2] [added: 597.7] | | | | | | [removed: 13] [added: 17] | | % | | | | [removed: 206.5] [added: 2.3] | | | | | | [removed: 53] [added: —] | | % |
| Other income (expense), net | | | [removed: 112.7] [added: 109.0] | | | | | | 3 | | % | | | | [removed: (0.4)] [added: 112.7] | | | | | | [removed: —] [added: 3] | | % | | | | [removed: 113.1] [added: (3.7)] | | | | | | [added: (3)] | | [added: %] |
| Income before income taxes | | | [removed: 710.4] [added: 709.0] | | | | | | [removed: 20] [added: 18] | | % | | | | [removed: 390.8] [added: 710.4] | | | | | | [removed: 13] [added: 20] | | % | | | | [removed: 319.6] [added: (1.4)] | | | | | | [removed: 82] [added: —] | | % |
| Income tax expense (benefit) | | | [removed: 168.9] [added: 132.8] | | | | | | [removed: 5] [added: 3] | | % | | | | [removed: 49.6] [added: 168.9] | | | | | | [removed: 2] [added: 5] | | % | | | | [removed: 119.3] [added: (36.1)] | | | | | | [added: (21)] | | [added: %] |
| Net income | | | $ | [removed: 541.5] [added: 576.2] | | | | | [removed: 15] [added: 14] | | % | | | | $ | [removed: 341.2] [added: 541.5] | | | | | [removed: 12] [added: 15] | | % | | | | $ | [removed: 200.3] [added: 34.7] | | | | | [removed: 59] [added: 6] | | % |
| Basic net income per share | | | $ | [removed: 1.40] [added: 1.46] | | | | | | | | | | | $ | [removed: 0.88] [added: 1.40] | | | | | | | | | | | $ | [removed: 0.52] [added: 0.06] | | | | | [removed: 59] [added: 4] | | % |
| Diluted net income per share | | | $ | [removed: 1.30] [added: 1.42] | | | | | | | | | | | $ | [removed: 0.82] [added: 1.30] | | | | | | | | | | | $ | [removed: 0.48] [added: 0.12] | | | | | [removed: 59] [added: 9] | | % |
Other income (expense), net consists primarily of interest and dividend income on our cash, cash equivalents and short-term marketable securities portfolio, foreign currency transaction gains and losses due to the effects of foreign currency fluctuations, [added: realized] and [added: unrealized gains and losses on equity investments, and] interest expense related to our senior convertible notes.
| [removed: | | | | | |] Twelve Months Ended December 31, [removed: 2023 Compared to Twelve] [added: 2024 Compared to Twelve] Months Ended December 31, [removed: 2022] [added: 2023] | | | [added: | | | | | | | | | | | |]
| Revenue | | | | | | The revenue increase was primarily driven by increased sales volume of our disposable sensors due to the continued growth of our worldwide customer [removed: base, partially] [added: base. We added approximately 500,000 - 600,000 net users, excluding Stelo customers, to our worldwide customer base in 2024. The increase in revenue was] offset by [removed: mix shift] [added: pricing headwinds due to greater rebate eligibility] and [removed: price associated with the evolution of our] channel [removed: and product strategy.] [added: mix.] Disposable sensor and other revenue comprised approximately [removed: 90%] [added: 95%] of total revenue and Reusable Hardware revenue comprised approximately [removed: 10%] [added: 5%] of total revenue for the twelve months ended December 31, [removed: 2023.] [added: 2024.] Disposable sensor and other revenue comprised approximately [removed: 87%] [added: 90%] of total revenue and Reusable Hardware revenue comprised approximately [removed: 13%] [added: 10%] of total revenue for the twelve months ended December 31, [removed: 2022.] [added: 2023.] | | |
| Research and development expense | | | | | | Research and development expense increased primarily due to [removed: $33.7] [added: $20.5] million in [removed: compensation-related] [added: compensation and related] costs [removed: most notably] due to higher headcount, [removed: partially offset by $15.9] [added: $11.2] million [removed: of lower third party] [added: in clinical trials, supplies] and [removed: consulting fees primarily related to] [added: other support costs, and $5.9 million in] software [removed: development for new products] and [removed: significant enhancements.] [added: data costs.] We continue to believe that focused investments in research and development are critical to our future growth and competitive position in the marketplace, and to the development of new and updated products and services that are central to our core business strategy. | | |
| Selling, general and administrative expense | | | | | | Selling, general and administrative expense increased primarily due to [removed: $88.8] [added: $33.5] million in [removed: compensation-related] [added: advertising and marketing costs, $30.7 million in compensation and related] costs [removed: most notably] due to higher headcount, [removed: $37.8] [added: $18.0] million in [removed: legal expense primarily related to a patent infringement lawsuit,] [added: software] and [removed: $36.6] [added: data costs, and $10.1] million in [removed: advertising and marketing costs associated with global product launches.] [added: travel related expenses.] | | |
| Income tax [removed: expense (benefit)] [added: expense] | | | | | | [removed: We recorded] [added: The] income tax expense [removed: on pre-tax book income] [added: recorded] for the twelve months ended December 31, [removed: 2023] [added: 2024 was primarily attributable to income tax expense from normal, recurring operations, partially offset by excess tax benefits recognized for share-based compensation for employees, net of nondeductible executive compensation, the Verily milestone payment, the impacts of certain foreign tax return filings] and [removed: December 31, 2022.] [added: generation of research and development tax credits.] The income tax expense [removed: we] recorded for [added: the twelve months ended December 31,] 2023 [removed: is] [added: was] primarily attributable to income tax expense from normal, recurring [removed: operations] [added: operations,] as well as income taxes related to an intra-entity transfer of certain intellectual property partially offset by excess tax benefits recognized for share-based compensation for employees (net of disallowed executive compensation) and the Verily milestone payment, and generation of research and development tax credits. The [removed: income] [added: decrease in our effective] tax [removed: expense we recorded] [added: rate] for [removed: 2022] [added: the twelve months ended December 31, 2024 compared to the same period in 2023] is primarily attributable to [removed: income tax expense from normal, recurring operations partially offset by excess tax benefits recognized for employee share-based compensation (net] [added: impacts] of [removed: disallowed executive compensation)] [added: the prior year tax restructuring] and the Verily [removed: milestone.] [added: milestone payment.] | | |
| | | | The evolution of the international expansion of our business and the revenue generated by sales of our approved products and [removed: other] [added: any] future products; | | | | | | | | | Our ability to efficiently scale our operations to meet demand for our current and any future products; | | | | | | | | | The success of our research and development efforts; | | | | | |
See [removed: “Foreign] [added: “*Foreign] Currency Exchange [removed: Risk”] [added: Risk*”] in Part II, Item 7A of this Annual Report on Form 10-K for more information.
Our cash, cash equivalents and short-term marketable securities totaled [removed: $2.72] [added: $2.58] billion as of December 31, [removed: 2023.][added: 2024.]
None of those funds were restricted and [removed: $2.54] [added: $2.36] billion (approximately [removed: 93%)] [added: 92%)] of those funds were located in the United States.
| $4.03 billion | | | | | | | | | $2.44 billion | | | | | | | | | $600.0 million | | | | | | | | | $576.2 million | | | | | | | | | $989.5 million | | |
| up 11% from 2023 | | | | | | | | | up 7% from 2023 | | | | | | | | | up 0.4% from 2023 | | | | | | | | | up 6% from 2023 | | | | | | | | | up 32% from 2023 | | |
| Revenue | | | $ | 4,033.0 | | | | | 100.0 | | % | | | | $ | 3,622.3 | | | | | 100.0 | | % | | | | $ | 410.7 | | | | | 11 | | % |
| Cost of sales | | | 1,594.8 | | | | | | 39.5 | | % | | | | 1,333.4 | | | | | | 36.8 | | % | | | | 261.4 | | | | | | 20 | | % |
We generate our revenue from the sale of disposable sensors and our reusable transmitter and receiver, collectively referred to as Reusable Hardware.
| | | | | | | Twelve Months Ended December 31, | | | | | | | | | | | | | | | | | | | | | | | | 2024 - 2023 | | | | | | | | |
| | | | | | | 2024 | | | | | | | | | | | | 2023 | | | | | | | | | | | | Change in Revenues | | | | | | | | |
| *(In millions)* | | | | | | Revenue | | | | | | % of Total | | | | | | Revenue | | | | | | % of Total | | | | | | $ | | | | | | % | | |
| United States | | | | | | $ | 2,889.8 | | | | | 72% | | | | | | $ | 2,625.3 | | | | | 72% | | | | | | $ | 264.5 | | | | | 10% | | |
| International | | | | | | 1,143.2 | | | | | | 28% | | | | | | 997.0 | | | | | | 28% | | | | | | 146.2 | | | | | | 15% | | |
| Total Revenue | | | | | | $ | 4,033.0 | | | | | 100% | | | | | | $ | 3,622.3 | | | | | 100% | | | | | | $ | 410.7 | | | | | 11% | | |
| | | | | | | Twelve Months Ended December 31, 2024 Compared to Twelve Months Ended December 31, 2023 | | |
| Cost of sales & Gross profit | | | | | | Cost of sales and gross profit increased primarily due to an increase in sales volume driven by the addition of approximately 500,000 - 600,000 net users, excluding Stelo customers, to our worldwide customer base in 2024. The decrease in gross profit margin percentage in 2024 compared to 2023 was primarily driven by product and channel mix changes, higher freight costs, and non-cash charges including a $22.7 million inventory build charge, and $20.6 million in inventory damaged in transit and certain build configurations that lowered production yield. | | |
| | | | | | | Twelve Months Ended December 31, 2024 Compared to Twelve Months Ended December 31, 2023 | | |
As of December 31, 2024, we have outstanding senior convertible notes classified as current that will mature in November 2025.
However, the outstanding principal of our senior convertible notes could be converted into cash and/or shares of our common stock prior to maturity once certain conditions are met.
Our obligations under the 2025 Notes and 2028 Notes include both principal and interest payments.
As market conditions warrant, we may, from time to time, repurchase our outstanding debt securities or shares of our common stock, in the open market, in privately negotiated transactions, by exchange transaction or otherwise.
Such repurchases, if any, will depend on prevailing market conditions, our liquidity and other factors and may be commenced or suspended at any time.
The amounts involved and total consideration paid may be material.
See Note 9 “*Stockholder’s Equity*—*Share Repurchase Program and Treasury Shares*” to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information about our 2024 Share Repurchase Program.
| $3.62 billion | | | | | | | | | $2.29 billion | | | | | | | | | $597.7 million | | | | | | | | | $541.5 million | | | | | | | | | $748.5 million | | |
| up 24% from 2022 | | | | | | | | | up 22% from 2022 | | | | | | | | | up 53% from 2022 | | | | | | | | | up 59% from 2022 | | | | | | | | | up 12% from 2022 | | |
| Revenue | | | $ | 3,622.3 | | | | | 100 | | % | | | | $ | 2,909.8 | | | | | 100 | | % | | | | $ | 712.5 | | | | | 24 | | % |
| Cost of sales | | | 1,333.4 | | | | | | 37 | | % | | | | 1,026.7 | | | | | | 35 | | % | | | | 306.7 | | | | | | 30 | | % |
Amortization of intangible assets
Our amortization expense primarily relates to acquired technology and intellectual property and other acquired intangible assets.
Income from equity investments
Income from equity investments is comprised of realized gains from the sale of an equity investment.
| Cost of sales & Gross profit | | | | | | Cost of sales and gross profit increased primarily due to an increase in sales volume. The decrease in gross profit margin in 2023 compared to 2022 was primarily driven by the increase of the amortization of an intangible asset and price, product, and channel mix changes. | | |
| Other income (expense), net | | | | | | Other income (expense), net, increased primarily due to $111.2 million in interest and dividend income on our cash, cash equivalents, and marketable securities portfolio. The increase in interest income was related to a change in market interest rates, as well as an increase in the average invested balances during 2023 compared to 2022. | | |
We issued our outstanding senior convertible notes in May 2020 and May 2023.
These obligations include both principal and interest for these notes.
An excerpt. Shown here: 40 of 77 rewritten, all 21 added and all 12 removed. The counts are complete. For every sentence, read Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS in the FY2024 filing and the FY2023 filing.
Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
3 rewritten, 0 added, 1 removed, 22 unchanged
Read the full itemFY2024 item · filed February 18, 2025FY2023 item · filed February 8, 2024
See Note 5 [removed: “Debt”] [added: “*Debt*”] to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information.
Fluctuations in the rate of exchange between the U.S. dollar and foreign [removed: currencies, primarily the Australian Dollar, the British Pound, the Canadian Dollar, the Euro, and the Malaysian Ringgit,] [added: currencies] could adversely affect our financial results, including income and losses as well as assets and liabilities in addition to risks to our revenues, revenue growth rates, and gross profit margins.
See Note 3 [removed: “Fair] [added: “*Fair] Value [removed: Measurements”] [added: Measurements*”] to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information.
The 2023 Warrants could have a dilutive effect on our earnings per share to the extent that the price of our common stock during a given quarterly or annual measurement period exceeds the strike price of the warrants.
Item 1. BUSINESS
83 rewritten, 29 added, 28 removed, 497 unchanged
Read the full itemFY2024 item · filed February 18, 2025FY2023 item · filed February 8, 2024
We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes [added: and metabolic health] by patients, caregivers, and clinicians around the world.
We launched our latest generation systems, the Dexcom [removed: G6*®*] [added: G6] integrated Continuous Glucose Monitoring System, or G6, in [removed: 2018] [added: 2018,] and [removed: more recently received marketing clearance from the FDA on] [added: we launched] the Dexcom [removed: G7*®*,] [added: G7,] or G7, in [removed: December 2022.][added: 2023.]
*Dexcom [removed: G6®*][added: G7*]
The G6 is designed to [added: automatically transfer data from the transmitter to the Dexcom receiver device as well as] allow our transmitter to run an algorithm to generate a glucose value and to communicate directly to a patient’s compatible mobile device, including iPhone®, iPod touch®, iPad®, and certain Android® mobile devices.
Data from the G6 can be integrated with Dexcom [removed: CLARITY®,] [added: Clarity,] our cloud-based reporting software, for personalized, easy-to-understand analysis of trends that may improve diabetes management.
In June 2018, we received [removed: Conformité Européenne Marking, or] CE [removed: Mark,] [added: Mark] approval for the G6, which allows us to market the system in the European Union and the countries in Asia and Latin America that recognize the CE Mark, as well as New Zealand, though certain countries may require compliance with certain local administrative requirements and/or additional marketing authorizations (for example, the inclusion of medical devices on the Australian Register of Therapeutic Goods in Australia).
In October 2019, we also received marketing authorization from the FDA for the Dexcom G6 Pro, or G6 Pro, which allows healthcare professionals to purchase the G6 for use [removed: with] [added: by] their patients.
*Dexcom [removed: G7®*][added: G6*]
In March 2022, we obtained [added: Conformité Européenne Marking, or] CE [removed: Mark] [added: Mark,] approval for G7.
Like the G6, the G7 is an [added: integrated continuous glucose monitoring system, or] iCGM, [added: and] is classified as a Class II device by the FDA, and is subject to special controls.
The glucose value algorithm, ability to communicate with approved display and mobile devices, and compatibility with [removed: CLARITY®] [added: Dexcom Clarity, our cloud-based reporting software,] are all substantially equivalent in technical performance and capability to the G6.
- An even more discreet and low profile. A redesigned transmitter makes for an all-in-one [removed: wearable] [added: wearable,] combining our sensor and transmitter that is 60% smaller than the G6, making it even more comfortable and easier to wear under clothing.
[removed: *Dexcom Stelo*®][added: *Stelo*]
*Dexcom [removed: Share*®][added: Share*]
The Dexcom Share remote monitoring system, offered for use with any current Dexcom system, uses an app on the patient’s compatible iPhone, iPod touch, iPad or Android mobile device to securely and wirelessly transmit glucose information to the cloud and then to apps on the mobile devices of up to [removed: five] [added: ten] designated recipients, or “followers,” who can remotely monitor a patient’s glucose information and receive alert notifications anywhere they have a wireless connection.
[removed: *Dexcom] [added: Dexcom] Real-Time [removed: API*][added: API]
*Dexcom [removed: ONE®*][added: ONE*]
[added: The general purpose of these development and commercial relationships is] to integrate our technology into the insulin pump or pen product offerings of the respective partner, enabling the partner’s insulin delivery device to receive and display glucose readings from our transmitter and, in some cases, use the glucose readings for semi-automated insulin delivery.
Our Restated Collaboration Agreement with Verily Life Science LLC (an Alphabet Company) and Verily Ireland Limited (collectively, Verily) provides us with an exclusive license to use intellectual property of Verily resulting from the collaboration, and certain Verily patents, in the development, manufacture and commercialization of blood-based or interstitial glucose monitoring products more generally (subject to certain exclusions, which are outside [added: of] the CGM field as it is commonly understood).
In consideration of Verily’s performance of its obligations under the joint development plan of the Restated Collaboration Agreement, the licenses granted to us and the amendment of the original agreement, we [removed: have] made upfront, incentive, [added: and the] product regulatory approval [removed: milestone] payments, and [removed: a] [added: payments for contingent] sales-based [removed: milestone payment.][added: milestones upon the achievement of certain revenue targets.]
See Note 2 [removed: “Development] [added: “*Development] and Other [removed: Agreements”] [added: Agreements*”] to the consolidated financial statements in Part II, Item 8 of this Annual Report and Exhibit [removed: 10.14] [added: 10.13] of this Annual Report on Form 10-K for a further description of the Restated Collaboration Agreement, including the number of shares of stock for milestone payments.
According to the Centers for Disease Control and Prevention, or CDC, in its National Diabetes Statistics Report, [removed: 2023,] [added: 2024,] or the [removed: 2023] [added: 2024] CDC Report, crude estimates for the prevalence of diabetes in the United States as of 2021 include 38.4 million people with diabetes, of which 29.7 million people have diagnosed diabetes.
[added: According to the American Diabetes Association, or ADA, one in every four healthcare dollars] was spent on treating people with diabetes in 2022, and the direct medical costs and indirect expenditures attributable to diabetes in the United States were an estimated $413 billion, an inflation-adjusted increase of approximately 35% since 2012.
According to the [removed: 2023] [added: 2024] CDC Report, as of 2021 there were an estimated 2.0 million adults and youth with diagnosed Type 1 diabetes in the United States.
][added: Chart.jpg](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm-20241231_g2.jpg)]
Our objective is to remain a leading provider of [removed: CGM systems] [added: glucose biosensors] and related products to enable people with diabetes [added: and those seeking] to [added: optimize metabolic health to] more effectively and conveniently manage their [removed: condition.][added: glucose levels.]
We are also exploring how to extend our offerings to other opportunities, including for people with [removed: Type 2 diabetes that are non-insulin using, people with] pre-diabetes, people who are obese, people who are pregnant, and people in the hospital setting.
- creating awareness of the benefits of continuous glucose monitoring and the advantages of our technology with endocrinologists, physicians, diabetes [removed: educators and] [added: educators,] people with [removed: diabetes;][added: diabetes and those seeking to optimize metabolic health;]
- maintaining a readily accessible telephone and web-based technical and customer support infrastructure, which includes clinicians, diabetes educators and reimbursement specialists, to help referring physicians, diabetes [removed: educators and] [added: educators,] people with diabetes [added: and those seeking to optimize metabolic health] as necessary.
Direct-to-consumer (DTC) marketing is one of our key initiatives to increase awareness of our CGM systems and drive new leads for people with diabetes [added: and those seeking] to [added: optimize metabolic health to] our website.
[removed: Collectively,] [added: Collectively with us,] these companies currently account for the majority of the worldwide sales of self-monitored glucose testing systems.
[added: Likewise, Abbott Diabetes Care has] received FDA clearance to integrate certain versions of their Libre sensors into automated insulin delivery systems and is pursuing such integrations with third-party insulin delivery devices.
- brand awareness and strong acceptance by healthcare [removed: professionals and] [added: professionals,] people with [removed: diabetes;][added: diabetes and those seeking to optimize metabolic health;]
- customer service and support and comprehensive education for people with [removed: diabetes and] [added: diabetes,] diabetes care [removed: providers;][added: providers and those seeking to optimize metabolic health;]
We currently manufacture our products at our headquarters in San Diego, California and at our manufacturing facilities in Mesa, Arizona and Penang, Malaysia, where we collectively have approximately [removed: 65,900] [added: 80,600] square feet of laboratory space and approximately [removed: 155,700] [added: 159,600] square feet of controlled environment rooms.
We anticipate that the new [removed: facilities and the Mesa capacity scale-up] [added: facility] will add substantial manufacturing capacity.
[removed: We] [added: While we] have focused significant effort on continual improvement programs in our manufacturing operations intended to improve quality, yields and [removed: throughput.][added: throughput, we cannot guarantee that we will be able to produce an adequate supply of product to support our commercialization efforts.]
Additionally, the production of our continuous glucose monitoring systems must occur in a highly controlled and clean environment to minimize particles and other [removed: yield-] [added: yield-limiting] and quality-limiting contaminants.
As of December 31, [removed: 2023,] [added: 2024,] those single sources include suppliers of application-specific integrated circuits used in our transmitters, seals used for the applicator and certain polymers used to synthesize polymeric membranes for our sensors.
For additional information, please see our Risk Factor [removed: entitled,] [added: entitled] “*We depend upon third-party suppliers and outsource to other parties, making us vulnerable to supply disruptions, suboptimal quality, non-compliance and/or price fluctuations, which could harm our [removed: business*.”][added: business.*”]
In August 2024, we launched Stelo, our new biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin, as the first over-the-counter glucose biosensor in the U.S.
In August 2024, we launched Stelo, our new biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin, as the first over-the-counter glucose biosensor in the U.S.
In connection with the Restated Collaboration Agreement, we developed, launched and commercialized a CGM product in connection with the collaboration.
With the introduction of Stelo, we are also pursuing and supporting development partnerships with consumer technology product companies that seek to provide metabolic health insights to their customers.
We are currently building out a new manufacturing facility in Athenry, Ireland.
We have recently experienced manufacturing and inventory challenges for G7 that have resulted, and may continue to result from time to time, in disruptions in our ability to supply certain markets, including in the U.S. and other
countries.
While we are currently working to remedy such challenges, we cannot predict when such manufacturing and inventory challenges will be remedied.
If we fail to produce a sufficient amount of our products, our ability to supply our markets will be compromised and health care providers and people with diabetes’ decisions to use our products may be negatively impacted.
This could lead to loss of sales of and revenues from our products, could potentially decrease our market share, and/or our business, financial condition, results of operations and growth prospects could be materially adversely affected.
See the section of the Risk Factors entitled “*Risks Related to Manufacturing, Commercial Operations and Commercialization.*”
was filed.
In addition, the Nominating and Governance Committee oversees and reviews our sustainability performance and the assessment and management of environmental, sustainability and governance risks affecting our business.
term strategy, taking into consideration environmental, social and economic dimensions (subject to direction from the Chief Executive Officer and oversight of the Nominating and Governance Committee), establishing programs, policies and practices to integrate sustainability into Dexcom’s strategy, and assisting the Nominating and Governance Committee in fulfilling its oversight responsibilities with respect to Dexcom’s performance and behavior for sustainability matters.
Under FDA law, the *de novo* classification procedure allows a manufacturer whose novel
into these programs have resulted in significant civil and criminal settlements.
HIPAA’s Security Rule and certain provisions of the HIPAA Privacy Rule and Breach Notification Rule apply to business associates of
CMS has the right to audit reporting entities for compliance.
CMS began its first audits in fiscal year 2023.
Singapore regulation of medical devices under the Health Products Act, and Health Canada’s risk classification system for invasive devices, among others.
Certain governments around the world are also adopting laws and regulations pertaining to mandatory corporate sustainability reporting.
For example, the European Union has adopted the Corporate Sustainability Reporting Directive (CSRD) that will require us to disclose certain social, governance and environmental information and data.
other areas to assist us as necessary.
Our consistent support of hybrid work provides access to a broader talent pool.
| United States | | | | | | 2,400 | | | | | | 2,900 | | | | | | 5,300 | | | | | | 3,100 | | |
| International | | | | | | 2,700 | | | | | | 2,300 | | | | | | 5,000 | | | | | | N/A | | |
| Grand Total | | | | | | 5,100 | | | | | | 5,200 | | | | | | 10,300 | | | | | | 3,100 | | |
Our human resources team, Employee Resource Group sponsors (ERG), and senior leaders work together to advance the broader equity strategy across the organization.
We integrate equity and inclusion into talent conversations, especially at senior levels, making our processes fairer for all Dexcom employees.
We are pursuing regulatory approvals for Dexcom Stelo, our first product designed specifically for people with type 2 diabetes who do not use insulin and are not at risk for hypoglycemia.
Stelo was submitted for FDA review in the fourth quarter of 2023.
The general purpose of these development and commercial relationships is
In the future, we may make a potential additional milestone payment for a future sales-based milestone.
At our election, we may make these payments in shares of our common stock or cash.
If we elect to make a milestone payment in cash, any such cash payment would be equal to the number of shares that would otherwise be issued for the given milestone payment multiplied by the value of our stock on the date the relevant milestone is achieved, adjusted for stock splits, dividends, and the like.
We intend to pay the remaining sales-based contingent milestone in shares of our common stock.
According to the American Diabetes Association, or ADA, one in every four healthcare dollars
Likewise, Abbott Diabetes Care has
In 2023, we completed the initial phase of construction of our new facility in Malaysia and commenced commercial manufacturing.
We are also expanding our facility in Mesa, Arizona to scale up manufacturing capacity and plan to begin construction of a new facility in Ireland.
We have made progress in manufacturing to enable us to supply adequate amounts of product to support our commercialization efforts, however we cannot guarantee that supply will not be constrained going forward.
or assignment terms of these agreements.
These values are at the heart of our sustainability initiatives.
payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid.
Inducement CMP.
disclosure of personally identifiable information.
Certain states also
data outside of Europe.
With our shift from office to hybrid work, we have access to more – and more diverse – talent than ever before.
Approximately 64% of our full-time U.S. employees are ethnically diverse.
| United States | | | | | | 2,600 | | | | | | 3,200 | | | | | | 5,800 | | | | | | 3,700 | | |
| International | | | | | | 2,100 | | | | | | 1,700 | | | | | | 3,800 | | | | | | N/A | | |
| Grand Total | | | | | | 4,700 | | | | | | 4,900 | | | | | | 9,600 | | | | | | 3,700 | | |
Our talent and diversity staff and the DEI Leadership Council, or DLC, are a means for leaders to work closely together to advance the broader DEI strategy across the organization.
We continue to weave DEI into talent conversations, particularly at senior levels, which we believe has contributed to our improved representation of female leaders at Dexcom.
Additionally, in 2023 we identified and engaged a third party consultant to help further evolve our gender and ethnicity pay equity review.
At this time, our employees have completed over 40,000 hours dedicated to this learning.
An excerpt. Shown here: 40 of 83 rewritten, all 29 added and all 28 removed. The counts are complete. For every sentence, read Item 1. BUSINESS in the FY2024 filing and the FY2023 filing.
Item 3. LEGAL PROCEEDINGS
6 rewritten, 30 added, 9 removed, 25 unchanged
Read the full itemFY2024 item · filed February 18, 2025FY2023 item · filed February 8, 2024
[removed: Since] [added: From] June [removed: 2021,] [added: 2021 through December 2024,] we and certain Abbott Diabetes Care, Inc. (“Abbott”) entities [removed: have] served patent infringement complaints against each other in multiple jurisdictions against certain continuous glucose monitoring products of each company.
Three trials on liability [removed: have already been] [added: were] conducted in the United Kingdom.
On January 15, 2024, judgment was handed down invalidating both Abbott and Dexcom’s [removed: patents in another one of these trials.][added: patents.]
Abbott’s patent infringement [removed: action, “D1",] [added: trial, “D1”,] against Dexcom [removed: is currently scheduled for trial] [added: commenced] in the U.S.D.C., District of Delaware [removed: on] [added: in] March [removed: 11,] 2024.
The claims [removed: currently being] litigated [removed: are] [added: were] isolated to the inserter mechanism and the wearable seal and mount of Dexcom’s G6.
Commencing in January 2024, [removed: Abbott has several] patent infringement hearings [removed: against] [added: between Abbott and] Dexcom [added: were scheduled to take place] in Germany [removed: (N.C. in Hamburg and Munich)] wherein [removed: Abbott is seeking] [added: each sought] damages and injunctive [removed: relief.][added: relief against the other.]
Litigation and Settlement with Abbott
On October 18, 2023 and June 28, 2024, judgment was handed down in favor of Dexcom, finding the Abbott patents to be invalid and not infringed.
On March 22, 2024, a jury returned a mixed verdict.
The jury found that Dexcom infringes one patent, that Dexcom did not infringe a second patent, and that Dexcom also did not infringe a third patent, which the jury also found invalid.
The jury found that any infringement was not willful.
It could not reach unanimity as to a fourth patent.
No determination of damages was made or awarded.
All but one of Abbott’s offensive hearings were either stayed or cancelled entirely due to parallel invalidity proceedings and nullity decisions.
After a February 28, 2024 hearing in Munich wherein Abbott asserted patent infringement claims against Dexcom, Dexcom received a favorable non-infringement decision.
On July 24, 2024, Dexcom received a decision from the Munich court related to the July 3, 2024 hearing, staying our offensive infringement proceedings pending the outcome of an opposition proceeding.
On July 31, 2024, Dexcom received a decision from the Munich courts related to hearings in April 2024, dismissing our claims for infringement.
On November 6, 2024, Dexcom received a favorable decision from the Munich District Court, finding Abbott infringes Dexcom’s patent and granting an injunction regarding Abbott’s LibrLinkUp application in Germany.
Under the Settlement Agreement described below, Abbott obtained a license to such patent and the injunction no longer applies.
In July 2024, after hearings in May and June in the Paris and Munich divisions of the UPC, each division issued a decision revoking our patents asserted against Abbott.
On December 20, 2024, Dexcom and Abbott entered into a settlement and patent cross license agreement (the “Settlement Agreement”) to resolve all outstanding patent litigation between the parties (the “Litigation”).
Under the terms of the Settlement Agreement, Dexcom granted Abbott and its affiliates, and Abbott and its affiliates granted Dexcom and its affiliates, a worldwide, royalty-free, non-exclusive, fully paid-up license to certain patents and patent applications relating to analyte sensing, including to all the patents asserted in the Litigation.
The Settlement Agreement does not obligate Dexcom or Abbott to pay any royalties or any other form of financial compensation.
As part of the Settlement Agreement, each party, on behalf of itself and its affiliates, has also (i) entered into a covenant not to sue until December 20, 2034; and (ii) agreed on behalf of themselves and their affiliates to refrain from challenging the patents and patent applications licensed under the Settlement Agreement for periods of time which vary depending on the relevant patents or patent applications.
The description of the Settlement Agreement contained herein is qualified in its entirety by reference to the Settlement Agreement, a copy of which is filed as Exhibit 10.16 to this Annual Report on Form 10-K.
Securities Class Action Litigation
Between August 21 and October 9, 2024, three substantially similar putative class action complaints were filed against us and certain of our executive officers in the United States District Court for the Southern District of California.
On December 13, 2024, the court appointed lead plaintiff court and consolidated the three actions (now captioned In Re: Dexcom, Inc. Class Action Securities Litigation, Lead Case No.: 24-cv-1485-RSH-VET).
On January 27, 2025, lead plaintiff filed a consolidated complaint.
The consolidated complaint alleges violations of the Securities Exchange Act against us and certain of our current and former executive officers for allegedly making false and misleading statements between April 28, 2023 and July 25, 2024, with respect to our expected revenue for fiscal 2024 and ability to capitalize on our growth potential.
Our deadline to respond to the consolidated complaint is March 13, 2025.
Derivative Actions
Between September 13 and October 16, 2024, two putative stockholders filed derivative lawsuits against us and certain of our current and former executive officers and directors in the United States District Court for the Southern District of California.
The derivative complaints allege factual allegations largely tracking allegations made in the Securities Class Action Litigation and seek, among other things, damages and restitution to be paid to the Company by the individual defendants, punitive damages, and attorney’s fees and costs.
On December 16, 2024, the court issued an order (i) consolidating the derivative actions, (ii) appointing lead counsel in the consolidated action (captioned In Re: Dexcom, Inc. Stockholder Derivative Litigation, Lead Case No.: 24-cv-1645-RSH-VET), and (iii) staying the consolidated action until the court’s resolution of any motions to dismiss in the Securities Class Action Litigation.
We intend to vigorously defend against such claims; however, we cannot be certain of the outcome of our ongoing proceedings and, if determined adversely to us, our business and financial condition may be adversely affected.
On October 18, 2023, judgment was handed down in favor of Dexcom in one of these trials.
The parties are awaiting rulings on the remaining trial.
Dexcom and Abbott sought injunctive relief and monetary damages as a result of their respective claims.
We will continue to enforce the remaining claims of the patents asserted in Delaware with trial set for February 2025.
On January 31, 2024, the Court in Munich in two such hearings provided Dexcom additional time to brief certain issues Abbott raised late in the proceedings, thus postponing a decision in both proceedings until May 2024.
In March and April of 2024, Dexcom has several patent infringement hearings in the N.C. in Mannheim and Munich against Abbott, wherein Dexcom is seeking damages and injunctive relief.
Dexcom has hearings in May and June 2024 in its first two proceedings in the UPC and in July 2024 in the N.C. in Munich.
Due to uncertainty surrounding patent litigation procedures initiated by Dexcom and Abbott throughout multiple jurisdictions, we are unable to reasonably estimate the ultimate outcome of any of the litigation matters at this time.
We intend to protect our intellectual property and defend against Abbott’s claims vigorously in all of these actions.
Cover and table of contents
43 rewritten, 6 added, 6 removed, 91 unchanged
Read the full itemFY2024 item · filed February 18, 2025FY2023 item · filed February 8, 2024
For the fiscal year ended December 31, [removed: 2023][added: 2024]
[removed: ][added: ]
[added: |] 6340 Sequence [removed: Drive, San Diego, CA 92121][added: Drive, San Diego, CA | | | | | | 92121 | | |]
[added: |] (Address of principal executive [removed: offices, including zip code)][added: offices) | | | | | | (Zip Code) | | |]
[removed: Securities] [added: Securities] registered pursuant to Section 12(g) of the Act: [removed: None][added: None]
As of June [removed: 30, 2023,] [added: 28, 2024,] the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was approximately [removed: $49.4] [added: $45.3] billion based on the closing sales price of [removed: $128.51] [added: $113.38] per share as reported on the Nasdaq Global Select Market on that date.
| Class | | | | | | Outstanding at February [removed: 1, 2024] [added: 6, 2025] | | |
| Common stock, $0.001 par value per share | | | | | | [removed: 385,515,421] [added: 390,772,018] | | |
Portions of the registrant’s definitive proxy statement relating to its [removed: 2024] [added: 2025] Annual Meeting of Stockholders (the “Proxy Statement”) are incorporated by reference in Part III, Items 10 through 14 of this Annual Report on Form 10-K, as specified in the responses to those item numbers, which proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year covered by this Form 10-K.
| [removed: PART I] [added: [PART I](#i6a987b433ae84cbfb2328647e6586107_25)] | | | | | | | | |
| [ITEM [removed: 1.](#i70f957301cc34339a22f629982cd0734_16)] [added: 1.](#i6a987b433ae84cbfb2328647e6586107_25)] | | | [removed: [Business](#i70f957301cc34339a22f629982cd0734_16)] [added: [Business](#i6a987b433ae84cbfb2328647e6586107_25)] | | | [removed: [6](#i70f957301cc34339a22f629982cd0734_16)] [added: [6](#i6a987b433ae84cbfb2328647e6586107_25)] | | |
| [ITEM [removed: 1A.](#i70f957301cc34339a22f629982cd0734_19)] [added: 1A.](#i6a987b433ae84cbfb2328647e6586107_64)] | | | [Risk [removed: Factors](#i70f957301cc34339a22f629982cd0734_19)] [added: Factors](#i6a987b433ae84cbfb2328647e6586107_64)] | | | [removed: [26](#i70f957301cc34339a22f629982cd0734_19)] [added: [27](#i6a987b433ae84cbfb2328647e6586107_64)] | | |
| [ITEM [removed: 1B.](#i70f957301cc34339a22f629982cd0734_67)] [added: 1B.](#i6a987b433ae84cbfb2328647e6586107_112)] | | | [Unresolved Staff [removed: Comments](#i70f957301cc34339a22f629982cd0734_67)] [added: Comments](#i6a987b433ae84cbfb2328647e6586107_112)] | | | [removed: [67](#i70f957301cc34339a22f629982cd0734_67)] [added: [69](#i6a987b433ae84cbfb2328647e6586107_112)] | | |
| [ITEM [removed: 2.](#i70f957301cc34339a22f629982cd0734_70)] [added: 2.](#i6a987b433ae84cbfb2328647e6586107_118)] | | | [removed: [Properties](#i70f957301cc34339a22f629982cd0734_70)] [added: [Properties](#i6a987b433ae84cbfb2328647e6586107_118)] | | | [removed: [69](#i70f957301cc34339a22f629982cd0734_70)] [added: [71](#i6a987b433ae84cbfb2328647e6586107_118)] | | |
| [ITEM [removed: 3.](#i70f957301cc34339a22f629982cd0734_73)] [added: 3.](#i6a987b433ae84cbfb2328647e6586107_121)] | | | [Legal [removed: Proceedings](#i70f957301cc34339a22f629982cd0734_73)] [added: Proceedings](#i6a987b433ae84cbfb2328647e6586107_121)] | | | [removed: [69](#i70f957301cc34339a22f629982cd0734_73)] [added: [71](#i6a987b433ae84cbfb2328647e6586107_121)] | | |
| [ITEM [removed: 4.](#i70f957301cc34339a22f629982cd0734_76)] [added: 4.](#i6a987b433ae84cbfb2328647e6586107_124)] | | | [Mine Safety [removed: Disclosures](#i70f957301cc34339a22f629982cd0734_76)] [added: Disclosures](#i6a987b433ae84cbfb2328647e6586107_124)] | | | [removed: [70](#i70f957301cc34339a22f629982cd0734_76)] [added: [73](#i6a987b433ae84cbfb2328647e6586107_124)] | | |
| [ITEM [removed: 5.](#i70f957301cc34339a22f629982cd0734_82)] [added: 5.](#i6a987b433ae84cbfb2328647e6586107_130)] | | | [Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity [removed: Securities](#i70f957301cc34339a22f629982cd0734_82)] [added: Securities](#i6a987b433ae84cbfb2328647e6586107_130)] | | | [removed: [71](#i70f957301cc34339a22f629982cd0734_82)] [added: [74](#i6a987b433ae84cbfb2328647e6586107_130)] | | |
| [ITEM [removed: 6.](#i70f957301cc34339a22f629982cd0734_85)] [added: 6.](#i6a987b433ae84cbfb2328647e6586107_133)] | | | [removed: [\[Reserved\]](#i70f957301cc34339a22f629982cd0734_85)] [added: [\[Reserved\]](#i6a987b433ae84cbfb2328647e6586107_133)] | | | [removed: [72](#i70f957301cc34339a22f629982cd0734_85)] [added: [75](#i6a987b433ae84cbfb2328647e6586107_133)] | | |
| [ITEM [removed: 7.](#i70f957301cc34339a22f629982cd0734_91)] [added: 7.](#i6a987b433ae84cbfb2328647e6586107_139)] | | | [Management’s Discussion and Analysis of Financial Condition and Results of [removed: Operations](#i70f957301cc34339a22f629982cd0734_91)] [added: Operations](#i6a987b433ae84cbfb2328647e6586107_139)] | | | [removed: [73](#i70f957301cc34339a22f629982cd0734_91)] [added: [76](#i6a987b433ae84cbfb2328647e6586107_139)] | | |
| [ITEM [removed: 7A.](#i70f957301cc34339a22f629982cd0734_121)] [added: 7A.](#i6a987b433ae84cbfb2328647e6586107_163)] | | | [Quantitative and Qualitative Disclosures about Market [removed: Risk](#i70f957301cc34339a22f629982cd0734_121)] [added: Risk](#i6a987b433ae84cbfb2328647e6586107_163)] | | | [removed: [84](#i70f957301cc34339a22f629982cd0734_121)] [added: [87](#i6a987b433ae84cbfb2328647e6586107_163)] | | |
| [ITEM [removed: 8.](#i70f957301cc34339a22f629982cd0734_133)] [added: 8.](#i6a987b433ae84cbfb2328647e6586107_175)] | | | [Financial Statements and Supplementary [removed: Data](#i70f957301cc34339a22f629982cd0734_133)] [added: Data](#i6a987b433ae84cbfb2328647e6586107_175)] | | | [removed: [85](#i70f957301cc34339a22f629982cd0734_133)] [added: [88](#i6a987b433ae84cbfb2328647e6586107_175)] | | |
| [ITEM [removed: 9.](#i70f957301cc34339a22f629982cd0734_136)] [added: 9.](#i6a987b433ae84cbfb2328647e6586107_178)] | | | [Changes in and Disagreements with Accountants on Accounting and Financial [removed: Disclosure](#i70f957301cc34339a22f629982cd0734_136)] [added: Disclosure](#i6a987b433ae84cbfb2328647e6586107_178)] | | | [removed: [85](#i70f957301cc34339a22f629982cd0734_136)] [added: [88](#i6a987b433ae84cbfb2328647e6586107_178)] | | |
| [ITEM [removed: 9A.](#i70f957301cc34339a22f629982cd0734_139)] [added: 9A.](#i6a987b433ae84cbfb2328647e6586107_181)] | | | [Controls and [removed: Procedures](#i70f957301cc34339a22f629982cd0734_139)] [added: Procedures](#i6a987b433ae84cbfb2328647e6586107_181)] | | | [removed: [86](#i70f957301cc34339a22f629982cd0734_139)] [added: [89](#i6a987b433ae84cbfb2328647e6586107_181)] | | |
| [ITEM [removed: 9B.](#i70f957301cc34339a22f629982cd0734_142)] [added: 9B.](#i6a987b433ae84cbfb2328647e6586107_187)] | | | [Other [removed: Information](#i70f957301cc34339a22f629982cd0734_142)] [added: Information](#i6a987b433ae84cbfb2328647e6586107_187)] | | | [removed: [88](#i70f957301cc34339a22f629982cd0734_142)] [added: [91](#i6a987b433ae84cbfb2328647e6586107_187)] | | |
| [ITEM [removed: 9C.](#i70f957301cc34339a22f629982cd0734_145)] [added: 9C.](#i6a987b433ae84cbfb2328647e6586107_193)] | | | [Disclosure Regarding Foreign Jurisdictions that Prevent [removed: Inspections](#i70f957301cc34339a22f629982cd0734_145)] [added: Inspections](#i6a987b433ae84cbfb2328647e6586107_193)] | | | [removed: [88](#i70f957301cc34339a22f629982cd0734_145)] [added: [91](#i6a987b433ae84cbfb2328647e6586107_193)] | | |
| [removed: PART III] [added: [PART III](#i6a987b433ae84cbfb2328647e6586107_196)] | | | | | | | | |
| [ITEM [removed: 10.](#i70f957301cc34339a22f629982cd0734_151)] [added: 10.](#i6a987b433ae84cbfb2328647e6586107_199)] | | | [Directors, Executive Officers and Corporate [removed: Governance](#i70f957301cc34339a22f629982cd0734_151)] [added: Governance](#i6a987b433ae84cbfb2328647e6586107_199)] | | | [removed: [89](#i70f957301cc34339a22f629982cd0734_151)] [added: [92](#i6a987b433ae84cbfb2328647e6586107_199)] | | |
| [ITEM [removed: 11.](#i70f957301cc34339a22f629982cd0734_154)] [added: 11.](#i6a987b433ae84cbfb2328647e6586107_202)] | | | [Executive [removed: Compensation](#i70f957301cc34339a22f629982cd0734_154)] [added: Compensation](#i6a987b433ae84cbfb2328647e6586107_202)] | | | [removed: [89](#i70f957301cc34339a22f629982cd0734_154)] [added: [92](#i6a987b433ae84cbfb2328647e6586107_202)] | | |
| [ITEM [removed: 12.](#i70f957301cc34339a22f629982cd0734_157)] [added: 12.](#i6a987b433ae84cbfb2328647e6586107_205)] | | | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder [removed: Matters](#i70f957301cc34339a22f629982cd0734_157)] [added: Matters](#i6a987b433ae84cbfb2328647e6586107_205)] | | | [removed: [89](#i70f957301cc34339a22f629982cd0734_157)] [added: [92](#i6a987b433ae84cbfb2328647e6586107_205)] | | |
| [ITEM [removed: 13.](#i70f957301cc34339a22f629982cd0734_160)] [added: 13.](#i6a987b433ae84cbfb2328647e6586107_208)] | | | [Certain Relationships and Related Transactions, and Director [removed: Independence](#i70f957301cc34339a22f629982cd0734_160)] [added: Independence](#i6a987b433ae84cbfb2328647e6586107_208)] | | | [removed: [89](#i70f957301cc34339a22f629982cd0734_160)] [added: [92](#i6a987b433ae84cbfb2328647e6586107_208)] | | |
| [ITEM [removed: 14.](#i70f957301cc34339a22f629982cd0734_163)] [added: 14.](#i6a987b433ae84cbfb2328647e6586107_211)] | | | [Principal Accountant Fees and [removed: Services](#i70f957301cc34339a22f629982cd0734_163)] [added: Services](#i6a987b433ae84cbfb2328647e6586107_211)] | | | [removed: [89](#i70f957301cc34339a22f629982cd0734_163)] [added: [93](#i6a987b433ae84cbfb2328647e6586107_211)] | | |
| [ITEM [removed: 15.](#i70f957301cc34339a22f629982cd0734_169)] [added: 15.](#i6a987b433ae84cbfb2328647e6586107_217)] | | | [removed: [Exhibits](#i70f957301cc34339a22f629982cd0734_169)] [added: [Exhibits](#i6a987b433ae84cbfb2328647e6586107_217)] and [Financial Statement [removed: Schedules](#i70f957301cc34339a22f629982cd0734_169)] [added: Schedules](#i6a987b433ae84cbfb2328647e6586107_217)] | | | [removed: [90](#i70f957301cc34339a22f629982cd0734_169)] [added: [94](#i6a987b433ae84cbfb2328647e6586107_217)] | | |
| [ITEM [removed: 16.](#i70f957301cc34339a22f629982cd0734_172)] [added: 16.](#i6a987b433ae84cbfb2328647e6586107_220)] | | | [Form 10-K [removed: Summary](#i70f957301cc34339a22f629982cd0734_172)] [added: Summary](#i6a987b433ae84cbfb2328647e6586107_220)] | | | [removed: [92](#i70f957301cc34339a22f629982cd0734_172)] [added: [96](#i6a987b433ae84cbfb2328647e6586107_220)] | | |
*Except for historical financial information contained herein, the matters discussed in this Annual Report on Form 10-K may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, [added: or the Securities Act,] and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and subject to the safe harbor created by the [added: Private] Securities Litigation Reform Act of 1995.
Such statements include declarations regarding our operations, financial condition and prospects, and business strategies, and are based on management’s [removed: current* *intent,] [added: intent,] beliefs, expectations, and [removed: assumptions.][added: assumptions as of the date of this report.]
[removed: Prospective investors] [added: Investors] are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks, uncertainties and other factors, some of which are beyond our [removed: control; actual results could differ materially from those indicated or implied by such forward-looking statements.][added: control.]
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, but are not limited to: (i) that the information is of a preliminary nature and may be subject to further adjustment; (ii) those risks and uncertainties identified under “Risk Factors”; and (iii) the other risks detailed from time-to-time in our [added: other] reports and registration statements filed with the Securities and Exchange Commission, or the SEC.
Also available on our website are printable versions of our Audit Committee charter, Compensation Committee charter, Nominating and Governance Committee charter, Technology Committee charter, Corporate Governance [removed: Guidelines] [added: Principles for the Board of Directors,] and Code of Conduct and Business Ethics.
Except as expressly set forth in this Annual Report on Form 10-K, the contents of our website [removed: is] [added: and/or our investor relations website are] not incorporated by reference into, or otherwise to be regarded as part of, this Annual Report on Form 10-K or in any other report or document we file with the SEC, and any references to our website [removed: is] [added: and/or our investor relations website are] intended to be inactive textual references only.
Other service marks, trademarks and trade names referred to in this [added: Annual Report on] Form 10-K are the property of their respective owners.
| [ITEM 1C.](#i6a987b433ae84cbfb2328647e6586107_115) | | | [Cybersecurity](#i6a987b433ae84cbfb2328647e6586107_115) | | | [69](#i6a987b433ae84cbfb2328647e6586107_115) | | |
| [PART II](#i6a987b433ae84cbfb2328647e6586107_127) | | | | | | | | |
| [PART IV](#i6a987b433ae84cbfb2328647e6586107_214) | | | | | | | | |
| | | | [Signatures](#i6a987b433ae84cbfb2328647e6586107_223) | | | [97](#i6a987b433ae84cbfb2328647e6586107_223) | | |
Actual results could differ materially from those indicated or implied by such forward-looking statements.
| Available Information | | | | | | | | | | | | | | |
| [I](#i70f957301cc34339a22f629982cd0734_3752)[TEM 1C.](#i70f957301cc34339a22f629982cd0734_3752) | | | [Cybersecurity](#i70f957301cc34339a22f629982cd0734_3752) | | | [67](#i70f957301cc34339a22f629982cd0734_3752) | | |
| PART II | | | | | | | | |
| PART IV | | | | | | | | |
| | | | [Signatures](#i70f957301cc34339a22f629982cd0734_175) | | | [93](#i70f957301cc34339a22f629982cd0734_175) | | |
| Corporate Information | | | | | | | | | | | | | | |
- We are subject to cost-containment efforts by third-party payors that could result in reduced product pricing and/or sales of our products and cause a reduction in revenue.
An excerpt. Shown here: 40 of 43 rewritten, all 6 added and all 6 removed. The counts are complete. For every sentence, read Cover and table of contents in the FY2024 filing and the FY2023 filing.
Item 1C. CYBERSECURITY
5 rewritten, 5 added, 4 removed, 34 unchanged
Read the full itemFY2024 item · filed February 18, 2025FY2023 item · filed February 8, 2024
See “Risk Factors — Risks Related to Privacy and Security.” As cybersecurity threats become more frequent, sophisticated and coordinated, it is reasonably likely that we will be required to expend greater resources [removed: to continue to modify and enhance our protective measures] as we pursue our strategy [removed: that includes] [added: of continuously modifying and enhancing our protective measures while] developing and commercializing products that [removed: integrate] [added: incorporate] our CGM technologies [removed: into] [added: and integrate with the] insulin delivery systems or data platforms of our partners.
These reviews are provided at least [removed: quarterly.][added: annually.]
The Technology Committee receives management updates and reports, primarily through the Company’s Cybersecurity and Privacy Committee, [added: a multidisciplinary team responsible for the overall governance, decision-making, risk management, awareness and compliance for cybersecurity and privacy activities across the Company.]
Our PSO, also a co-chair of the committee, has over twenty-five years of previous experience in cyber security architecture and cyber security management for a number of large Fortune 500 technology companies and holds several certifications including CISSP from the International Information Security System Security Certification [removed: Consortium ,] [added: Consortium,] C-CISO from EC-Council, Numerous certifications from Microsoft, CISCO, Juniper, Checkpoint among others and has completed several advanced GIAC security classes from the SANS Institute.
Our [removed: PSO reports directly to our] Executive Vice President, Chief Technology Officer [removed: (CTO), who] [added: (CTO)] is also a member of the committee.
She has held this role at Dexcom since 2024 and is responsible for global information technology at Dexcom.
Our CIO brings 30 years of diverse strategic and operational experience in IT management, data engineering, AI, digital, ecommerce, infrastructure modernization and supply chain.
Prior to Dexcom, our CIO served as Senior Vice President, Chief Information Officer at Bausch + Lomb.
Additionally, our CIO has held transformational roles at Johnson & Johnson, Bristol Myers Squibb, American Standard and Price Waterhouse Coopers.
She holds a Bachelor of Science degree in Economics and Management Information Systems from the University of Delaware.
a multidisciplinary team responsible for the overall governance, decision-making, risk management, awareness and compliance for cybersecurity and privacy activities across the Company.
He has held this role at Dexcom since 2021, having previously served as our Senior Vice President, Information Technology since 2018 and Vice President, Information Technology from 2016 to 2018.
Our CIO also has a wide range of experience within global organizations in the field of information technology, including having served in various IT leadership roles at CareFusion, a Becton Dickinson Company, from 2012 to 2016, and ResMed in San Diego from 2007 to 2012.
He holds a Bachelor of Engineering in Mechanical Engineering and a Master of Industrial Engineering.
Item 2. PROPERTIES
2 rewritten, 3 added, 2 removed, 11 unchanged
Read the full itemFY2024 item · filed February 18, 2025FY2023 item · filed February 8, 2024
| (1) Excludes [removed: renewals] [added: a renewal] that would be at our option to extend the term of a lease expiring in 2028 for one additional three to five-year term. | | | | | | | | |
As of December 31, [removed: 2023,] [added: 2024,] we had approximately [removed: 65,900] [added: 80,600] square feet of laboratory space and approximately [removed: 155,700] [added: 159,600] square feet of controlled environment rooms.
| Athenry, Ireland | | | | | | 3023 (4) | | |
| (4) Represents a 999-year land lease with the Industrial Development Agency of Ireland. | | | | | | | | |
In addition, the construction of a new manufacturing facility in Athenry, Ireland is underway.
In 2023, we completed the initial phase of construction of our new facility in Malaysia and commenced commercial manufacturing.
We are also expanding our facility in Mesa, Arizona to scale up manufacturing capacity.
Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
6 rewritten, 1 added, 18 removed, 12 unchanged
Read the full itemFY2024 item · filed February 18, 2025FY2023 item · filed February 8, 2024
We had approximately [removed: 35] [added: 25] stockholders of record as of February [removed: 1, 2024.][added: 6, 2025.]
[removed: There were no other] [added: All] unregistered sales of equity securities [removed: which] have [removed: not] been previously disclosed in a [removed: quarterly report on] Form 10-Q or a current report on Form 8-K [removed: during] [added: for] the [removed: last three] fiscal [removed: years] [added: year] ended December 31, [removed: 2023.][added: 2024.]
[removed: Accordingly, the] [added: The] graph below compares the cumulative total stockholder return on our common stock with the cumulative total returns on the [removed: Nasdaq Composite index, the Nasdaq Medical Equipment index, the] S&P Health Care Equipment Select Industry [removed: index,] [added: index] and the S&P 500 index over the five-year period ended December 31, [removed: 2023.][added: 2024.]
The graph assumes that $100 was invested in Dexcom common stock and in each of the other indices on December 31, [removed: 2018] [added: 2019] and that all dividends were reinvested.
[removed: ][added: ]
* $100 invested on December 31, [removed: 2018] [added: 2019] in stock or index, including reinvestment of any dividends.
Neither we nor any affiliated purchaser repurchased any of our equity securities during the quarter ended December 31, 2024.
In connection with the accelerated share repurchase agreement with Bank of America, N.A., we issued 6,325 shares of our common stock in December 2023 in a private placement exempt from the registration requirements of the Securities Act in reliance on the exemption set forth in Section 4(a)(2) of the Securities Act.
On October 24, 2023, our Board of Directors authorized and approved a share repurchase program of up to $500.0 million of our outstanding common stock, with a repurchase period ending no later than October 31, 2024 (“2023 Share Repurchase Program”).
Under the 2023 Share Repurchase Program, on October 31, 2023, we entered into an accelerated share repurchase agreement (“2023 ASR”) with Bank of America, N.A. (“BofA”) to repurchase shares of our common stock in an aggregate notional amount of up to $500.0 million.
See Note 9 “Employee Benefit Plans and Stockholders' Equity” to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K for additional information about our share repurchases during the year ended December 31, 2023.
The following table provides information about purchases by us of our shares of common stock during the three months ended December 31, 2023:
| Period | | | | | | Total number of shares purchased | | | | | | Average price paid per share | | | | | | Total number of shares purchased as part of publicly announced program | | | | | | Maximum dollar value of shares that may yet be purchased under the program (in millions) | | |
| 10/01/2023 - 10/31/2023 | | | | | | 4,710,870 | | | | | | (1) | | | | | | 4,710,870 | | | | | | $ | 100.0 | |
| 11/01/2023 - 11/30/2023 | | | | | | — | | | | | | $ | — | | | | | — | | | | | | $ | 100.0 | |
| 12/01/2023 - 12/31/2023 | | | | | | — | | | | | | (1) | | | | | | — | | | | | | $ | — | |
| (1) Pursuant to the terms of the 2023 ASR, in October 2023, we paid BofA $500.0 million in cash and received an initial delivery of approximately 4.7 million shares of our common stock based on the closing market price on October 30, 2023 of $84.91. This initial delivery of shares represented approximately 80% of the notional amount of the 2023 ASR. On December 14, 2023, the 2023 ASR was settled. Based on the volume-weighted average price of our common stock, less a discount, of $106.28 during the term of the 2023 ASR, we owed BofA 6,325 shares of common stock. We elected to settle the forward contract by issuing 6,325 treasury shares on December 15, 2023 to BofA. | | | | | | | | | | | | | | | | | | | | | | | | | | |
Our 2022 Annual Report on Form 10-K included a comparison of the 5-year cumulative total return of our common stock with the Nasdaq Composite index and the Nasdaq Medical Equipment index.
As a result of the discontinuation of the Nasdaq Medical Equipment index in 2022, we believe that the S&P Health Care Equipment Select Industry index is a more appropriate index for comparison of our stock performance.
| | | | | | | December 31, 2018 | | | | | | December 31, 2019 | | | | | | December 31, 2020 | | | | | | December 31, 2021 | | | | | | December 31, 2022 | | | | | | December 31, 2023 | | |
| DexCom, Inc. | | | | | | $ | 100.00 | | | | | $ | 182.59 | | | | | $ | 308.61 | | | | | $ | 448.21 | | | | | $ | 378.10 | | | | | $ | 414.32 | |
| S&P 500 | | | | | | $ | 100.00 | | | | | $ | 131.49 | | | | | $ | 155.68 | | | | | $ | 200.37 | | | | | $ | 164.08 | | | | | $ | 207.21 | |
| S&P Health Care Equipment | | | | | | $ | 100.00 | | | | | $ | 122.72 | | | | | $ | 163.40 | | | | | $ | 169.11 | | | | | $ | 129.60 | | | | | $ | 122.26 | |
| Nasdaq Composite | | | | | | $ | 100.00 | | | | | $ | 136.69 | | | | | $ | 198.10 | | | | | $ | 242.03 | | | | | $ | 163.28 | | | | | $ | 236.17 | |
| Nasdaq Medical Equipment | | | | | | $ | 100.00 | | | | | $ | 97.52 | | | | | $ | 136.07 | | | | | $ | 140.62 | | | | | $ | 94.93 | | | | | | | |
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
2 rewritten, 0 added, 0 removed, 1 unchanged
Read the full itemFY2024 item · filed February 18, 2025FY2023 item · filed February 8, 2024
The information required is set forth under “Report of Independent Registered Public Accounting Firm,” “Consolidated Balance Sheets,” “Consolidated Statements of Operations,” “ Consolidated Statements of Comprehensive Income,” “Consolidated Statements of Stockholders’ Equity,” “Consolidated Statements of Cash Flows” and “Notes to Consolidated Financial Statements” on pages [removed: [F-10](#i70f957301cc34339a22f629982cd0734_199)] [added: [F-10](#i6a987b433ae84cbfb2328647e6586107_247)] to [removed: [F-4](#i70f957301cc34339a22f629982cd0734_370)[3](#i70f957301cc34339a22f629982cd0734_370)] [added: [F-47](#i6a987b433ae84cbfb2328647e6586107_475)] of this Annual Report and is incorporated into this Item 8 by reference.
Their consent appears as Exhibit [removed: 23.01] [added: 23.1] of this Form 10-K.
Item 9A. CONTROLS AND PROCEDURES
12 rewritten, 2 added, 1 removed, 31 unchanged
Read the full itemFY2024 item · filed February 18, 2025FY2023 item · filed February 8, 2024
[removed: Regulations under the Exchange Act, require public companies to maintain “disclosure] [added: Disclosure] controls and [removed: procedures,” which are defined to mean a company’s] [added: procedures include, without limitation,] controls and other procedures that are designed to ensure that information required to be disclosed in the reports that [removed: it files] [added: we file] or [removed: submits] [added: submit] under the Exchange [removed: Act,] [added: Act] is accumulated and timely communicated to management, including our Chief Executive Officer [added: (our principal executive officer)] and Chief Financial [removed: Officer,] [added: Officer (our principal financial officer),] recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms.
Our management, [removed: including] [added: with the participation of] our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation [added: of the effectiveness of our disclosure controls and procedures] as of the end of the period covered by this [removed: report of the effectiveness of our disclosure controls and procedures.][added: report.]
Based on their evaluation as of December 31, [removed: 2023,] [added: 2024,] our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective [added: at a reasonable assurance level] as of such [removed: date for this purpose.][added: date.]
There were no changes in our internal control over financial reporting [added: (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act)] during [removed: our last] [added: the most recently completed] fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Our management, with the participation of the Chief Executive and Chief Financial Officers, assessed the effectiveness of our internal control over financial reporting as of December 31, [removed: 2023.][added: 2024.]
Based on this assessment, our management, with the participation of the Chief Executive and Chief Financial Officers, believes that, as of December 31, [removed: 2023,] [added: 2024,] our internal control over financial reporting is effective based on those criteria.
The effectiveness of our internal control over financial reporting as of December 31, [removed: 2023] [added: 2024] has been audited by Ernst & Young LLP, an Independent Registered Public Accounting Firm, as stated in their report which is included herein.
The certifications of our Chief Executive Officer and Chief Financial Officer required under Section 302 of the Sarbanes-Oxley Act have been filed as Exhibits [removed: 31.01] [added: 31.1] and [removed: 31.02] [added: 31.2] to this report.
It should be noted that any system of controls, [added: including ours,] however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met.
We have audited DexCom, Inc.’s internal control over financial reporting as of December 31, [removed: 2023,] [added: 2024,] based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria).
In our opinion, DexCom, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, [removed: 2023,] [added: 2024,] based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of [removed: DexCom, Inc.] [added: the Company] as of December 31, [removed: 2023] [added: 2024] and [removed: 2022,] [added: 2023,] the related consolidated statements of operations, comprehensive income, stockholders’ equity and cash flows for each of the three years in the period ended December 31, [removed: 2023,] [added: 2024,] and the related notes and financial statement schedule listed in the Index at Item 15(a) and our report dated February [removed: 8, 2024] [added: 14, 2025] expressed an unqualified opinion thereon.
Regulations under the Exchange Act require public companies to maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act.
February 14, 2025
February 8, 2024
Item 9B. OTHER INFORMATION
1 rewritten, 0 added, 15 removed, 1 unchanged
Read the full itemFY2024 item · filed February 18, 2025FY2023 item · filed February 8, 2024
During the three months ended December 31, [removed: 2023, the following] [added: 2024, no] Section 16 officers [removed: and] [added: or] directors [removed: adopted] [added: adopted, modified,] or terminated a “Rule 10b5-1 trading arrangement” [removed: (as] [added: or “non-Rule 10b5-1 trading arrangement” (each as] defined in Item 408 of Regulation S-K of the Exchange [removed: Act):][added: Act).]
| Name | | | Title | | | Action | | | Action Date | | | Aggregate Number of Shares to be Sold(1) | | | Expiration Date(2) | | |
| Matthew Dolan | | | Executive Vice President, Strategy, Corporate Development and Dexcom Labs | | | Adoption | | | 12/15/2023 | | | 15,326 | | | 12/15/2024 | | |
| Paul Flynn | | | Executive Vice President, Global Revenue | | | Adoption | | | 12/15/2023 | | | 31,253 | | | 12/15/2024 | | |
| Girish Naganathan | | | Executive Vice President, Chief Technology Officer | | | Adoption | | | 11/20/2023 | | | 5,137 | | | 11/20/2024 | | |
| Steven R. Pacelli | | | Executive Vice President and Managing Director, Dexcom Ventures | | | Adoption | | | 11/27/2023 | | | 15,000 | | | 1/23/2025 | | |
| Barry J. Regan | | | Executive Vice President, Global Operations | | | Adoption | | | 12/4/2023 | | | 28,430 | | | 12/4/2024 | | |
| Kevin R. Sayer | | | Chairperson, President and Chief Executive Officer | | | Adoption | | | 12/12/2023 | | | 100,965 | | | 12/12/2024 | | |
| Sadie M. Stern | | | Executive Vice President, Chief Human Resources Officer | | | Adoption(3) | | | 12/12/2023 | | | 12,825 | | | 3/11/2025 | | |
| Sadie M. Stern | | | Executive Vice President, Chief Human Resources Officer | | | Termination(3) | | | 12/12/2023 | | | 4,708 | | | 3/8/2024 | | |
| Jereme M. Sylvain | | | Executive Vice President, Chief Financial Officer | | | Adoption | | | 11/21/2023 | | | 6,863 | | | 11/21/2024 | | |
| (1) The actual number of shares sold may depend on the net shares vested as a result of tax withholding obligations, the vesting of certain performance-based stock units, the number of shares purchased under employee stock purchase plans, one or more limit orders, as applicable, and therefore, may not be determinable at this time. | | | | | | | | | | | | | | | | | |
| (2) Except as indicated by footnote, each trading arrangement permitted or permits transactions through and including the date listed in the table. | | | | | | | | | | | | | | | | | |
| (3) Represents the modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written plan adopted on December 12, 2023 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), as then in effect, under the Exchange Act. | | | | | | | | | | | | | | | | | |
Each of the Rule 10b5-1 trading arrangements that were adopted in the above table are in accordance with our insider trading policy and actual sale transactions made pursuant to such trading arrangements will be disclosed publicly in Section 16 filings with the SEC in accordance with applicable securities laws, rules and regulations.
No Section 16 officers or directors adopted, modified, or terminated a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act) during the three months ended December 31, 2023.
Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
3 rewritten, 0 added, 0 removed, 6 unchanged
Read the full itemFY2024 item · filed February 18, 2025FY2023 item · filed February 8, 2024
This code of ethics, titled the “Code of Conduct and Business [removed: Ethics,”] [added: Ethics”,] is publicly available on our Internet website at [removed: https://dexcom.gcs-web.com/corporate-governance.][added: https://investors.dexcom.com/governance/governance-documents.]
The information concerning the Audit Committee of the Board of Directors required by this Item is incorporated by reference to the [removed: section] [added: sections] of the Proxy Statement entitled “Committees of the Board and [removed: Meetings - Audit Committee.”][added: Meetings” and “Meetings of the Board of Directors; Director Attendance.”]
The information concerning the Company’s insider trading policies and compliance with Section 16(a) required by this Item is incorporated by reference to the sections of the Proxy Statement entitled “Insider Trading [removed: Policy”] [added: Policy; Anti-Hedging”] and [removed: Delinquent] [added: “Delinquent] Section 16(a) [removed: Reports,] [added: Reports”,] respectively.
Item 11. EXECUTIVE COMPENSATION
1 rewritten, 0 added, 0 removed, 0 unchanged
Read the full itemFY2024 item · filed February 18, 2025FY2023 item · filed February 8, 2024
The information required by this Item concerning executive compensation and our Compensation Committee is incorporated by reference to the sections in the Proxy Statement entitled [removed: “Compensation Discussion and Analysis,” “2023] [added: “Executive Compensation,” “2024] Summary Compensation Table,” “Grants of Plan-Based [removed: Awards,”] [added: Awards for 2024,”] “Outstanding Equity Awards at December 31, [removed: 2023,” “2023] [added: 2024,” “2024] Option [removed: Awards] Exercises and Stock Vested,” “Executive Nonqualified Deferred Compensation Plan,” [removed: “Employment, Severance] [added: “Severance] and Change in Control Arrangements,” [removed: “2023] [added: “2024] Director [removed: Compensation,”] [added: Compensation Table,”] “Risks from Compensation Policies and Practices,” “Chief Executive Officer Pay Ratio,” “Compensation Committee [removed: Interlocks,”] [added: Interlocks] and [added: Insider Participation,” and] “Compensation Committee Report.”
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
1 rewritten, 0 added, 0 removed, 1 unchanged
Read the full itemFY2024 item · filed February 18, 2025FY2023 item · filed February 8, 2024
The information required by this Item with respect to director independence is incorporated by reference to the section in the Proxy Statement entitled [removed: “Corporate Governance - Director Independence”.][added: “Director Independence.”]
Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
1 rewritten, 0 added, 0 removed, 1 unchanged
Read the full itemFY2024 item · filed February 18, 2025FY2023 item · filed February 8, 2024
The information concerning principal accountant fees and services required by this Item is incorporated by reference to the section in the Proxy Statement entitled [removed: “Ratification] [added: “Proposal No. 2 – Ratification] of Independent Registered Public Accounting Firm.”
Item 15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES
39 rewritten, 4 added, 1 removed, 12 unchanged
Read the full itemFY2024 item · filed February 18, 2025FY2023 item · filed February 8, 2024
[Schedule II – Valuation and Qualifying [removed: Accounts](#i70f957301cc34339a22f629982cd0734_376).][added: Accounts](#i6a987b433ae84cbfb2328647e6586107_499).]
| Exhibit Number | | | | | | Exhibit Description | | | | | | Incorporated by Reference | | | | | | | | | | | | | | | | | | | | | | | | Provided Herewith | | | [removed: | | |]
| Form | | | | | | File No. | | | | | | Date of First Filing | | | | | | Exhibit Number | | | | | | | | | | | | | | | | | | | | | [removed: | | |]
| [removed: [3.](https://www.sec.gov/Archives/edgar/data/1093557/000119312522171920/d368741dex31.htm)[1](https://www.sec.gov/Archives/edgar/data/1093557/000119312522171920/d368741dex31.htm)] [added: 3.1] | | | | | | [Restated Certificate of Incorporation of DexCom, Inc.](https://www.sec.gov/Archives/edgar/data/1093557/000119312522171920/d368741dex31.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | June 10, 2022 | | | | | | 3.1 | | | | | | | | | [removed: | | |]
| [removed: [3.](http://www.sec.gov/Archives/edgar/data/0001093557/000119312521169442/d185301dex33.htm)[2](http://www.sec.gov/Archives/edgar/data/0001093557/000119312521169442/d185301dex33.htm)] [added: 3.2] | | | | | | [Amended and Restated Bylaws of DexCom, [removed: Inc.](http://www.sec.gov/Archives/edgar/data/0001093557/000119312521169442/d185301dex33.htm)] [added: Inc.](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000180/dxcm9302024exhibit31.htm)] | | | | | | [removed: 8-K] [added: 10-Q] | | | | | | 000-51222 | | | | | | [removed: May 21, 2021 | | |] [added: October 24, 2024] | | | [removed: 3.3] | | | [added: 3.1] | | | | | | | | |
| [removed: [4.](https://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm)[1](https://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm)] [added: 4.1] | | | | | | [Form of Specimen Certificate [removed: for](http://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm) [DexCom, Inc.](http://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm) [common stock.](http://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm)] [added: for DexCom, Inc. common stock.](https://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm)] | | | | | | S-1/A | | | | | | 333-122454 | | | | | | March 24, 2005 | | | | | | 4.01 | | | | | | | | | [removed: | | |]
| [removed: [4.](http://www.sec.gov/Archives/edgar/data/0001093557/000119312518340482/d667223dex41.htm)[2](http://www.sec.gov/Archives/edgar/data/0001093557/000119312518340482/d667223dex41.htm)] [added: 4.2] | | | | | | [Indenture, dated November 30, 2018, between DexCom, Inc. and U.S. Bank National Association (including the form of 0.75% Convertible Senior Notes due [removed: 2023).](http://www.sec.gov/Archives/edgar/data/0001093557/000119312518340482/d667223dex41.htm)] [added: 2023).](https://www.sec.gov/Archives/edgar/data/0001093557/000119312518340482/d667223dex41.htm)] | | | | | | 8-K | | | | | | 000-51222 | | | | | | December 3, 2018 | | | | | | 4.1 | | | | | | | | | [removed: | | |]
| [removed: [4.](http://www.sec.gov/Archives/edgar/data/0001093557/000119312520143408/d926678dex41.htm)[3](http://www.sec.gov/Archives/edgar/data/0001093557/000119312520143408/d926678dex41.htm)] [added: 4.3] | | | | | | [Indenture, dated May 14, 2020, between DexCom, Inc. and U.S. Bank National Association (including the form of 0.25% Convertible Senior Notes due [removed: 2025).](http://www.sec.gov/Archives/edgar/data/0001093557/000119312520143408/d926678dex41.htm)] [added: 2025).](https://www.sec.gov/Archives/edgar/data/0001093557/000119312520143408/d926678dex41.htm)] | | | | | | 8-K | | | | | | 000-51222 | | | | | | May 15, 2020 | | | | | | 4.1 | | | | | | | | | [removed: | | |]
| [removed: [4.4](https://www.sec.gov/Archives/edgar/data/1093557/000119312523137248/d300995dex41.htm)] [added: 4.4] | | | | | | [Indenture, dated May 5, 2023, between DexCom, Inc. and U.S. Bank Trust Company, National Association (including the form of 0.375% Convertible Senior Notes due 2028).](https://www.sec.gov/Archives/edgar/data/1093557/000119312523137248/d300995dex41.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | May 5, 2023 | | | | | | 4.1 | | | | | | | | | [removed: | | |]
| [removed: [4.5](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex45-securitie.htm)] [added: 4.5] | | | | | | [Description of Securities Registered Under Section 12 of the Exchange [removed: Act.](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex45-securitie.htm)] [added: Act.](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit45.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | [removed: | | |]
| [removed: [10.1*](http://www.sec.gov/Archives/edgar/data/1093557/000119312511208448/dex1028.htm)] [added: 10.1*] | | | | | | [Offer letter between DexCom, Inc. and Kevin Sayer, dated May 3, [removed: 2011.](http://www.sec.gov/Archives/edgar/data/1093557/000119312511208448/dex1028.htm)] [added: 2011.](https://www.sec.gov/Archives/edgar/data/1093557/000119312511208448/dex1028.htm)] | | | | | | 10-Q | | | | | | 000-51222 | | | | | | August 3, 2011 | | | | | | 10.28 | | | | | | | | | [removed: | | |]
| [removed: [10.2](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1036.htm)] [added: 10.2] | | | | | | [Sublease between DexCom, Inc. and Entropic Communications, [removed: LLC](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1036.htm)[,](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1036.htm) [dated] [added: LLC, dated] February 1, [removed: 2016.](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1036.htm)] [added: 2016.](https://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1036.htm)] | | | | | | 10-Q | | | | | | 000-51222 | | | | | | April 27, 2016 | | | | | | 10.36 | | | | | | | | | [removed: | | |]
| [removed: [10.3*](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000137/exhibit1002dexcomincexecut.htm)] [added: 10.3*] | | | | | | [DexCom, Inc. Executive Deferred Compensation [removed: Plan.](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000137/exhibit1002dexcomincexecut.htm)] [added: Plan.](https://www.sec.gov/Archives/edgar/data/1093557/000109355719000137/exhibit1002dexcomincexecut.htm)] | | | | | | 8-K | | | | | | 000-51222 | | | | | | June 4, 2019 | | | | | | 10.02 | | | | | | | | | [removed: | | |]
| [removed: [10.4](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1040.htm)] [added: 10.4] | | | | | | [Third Amendment to Office Lease between DexCom, Inc. and John Hancock Life Insurance Company, dated January 9, [removed: 2019.](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1040.htm)] [added: 2019.](https://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1040.htm)] | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 13, 2020 | | | | | | 10.40 | | | | | | | | | [removed: | | |]
| [removed: [10.5*](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex1043doindemn.htm)] [added: 10.5*] | | | | | | [Form of Indemnity Agreement between DexCom, Inc. and each of its directors and executive officers.](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex1043doindemn.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 11, 2021 | | | | | | 10.43 | | | | | | | | | [removed: | | |]
| [removed: [10.6*](http://www.sec.gov/Archives/edgar/data/0001093557/000109355721000084/dxcmex1012021bonusplan.htm)] [added: 10.6*] | | | | | | [DexCom, Inc. Incentive Bonus [removed: Plan.](http://www.sec.gov/Archives/edgar/data/0001093557/000109355721000084/dxcmex1012021bonusplan.htm)] [added: Plan.](https://www.sec.gov/Archives/edgar/data/0001093557/000109355721000084/dxcmex1012021bonusplan.htm)] | | | | | | 8-K | | | | | | 000-51222 | | | | | | March 17, 2021 | | | | | | 10.1 | | | | | | | | | [removed: | | |]
| [removed: [10.7](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm-12312021ex1039locamen.htm)] [added: 10.7] | | | | | | [Second Amended and Restated Credit Agreement dated October 13, 2021 by and among DexCom, Inc., Bank of America, Silicon Valley Bank and Union Bank, and JPMorgan Chase Bank, as Administrative Agent.](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm-12312021ex1039locamen.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 14, 2022 | | | | | | 10.39 | | | | | | | | | [removed: | | |]
| [removed: [10.8](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1009-officel.htm)] [added: 10.8] | | | | | | [Office Lease Agreement, dated March 31, 2006, between DexCom, Inc. and Kilroy Realty, L.P., as amended on August 18, 2010 and October 1, 2014.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1009-officel.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 9, 2023 | | | | | | 10.09 | | | | | | | | | [removed: | | |]
| [removed: [10.9](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1018-fourtha.htm)] [added: 10.9] | | | | | | [Fourth Amendment to Office Lease between DexCom, Inc. and Sequence Tech. Center CA LLC, dated September 9, 2019, as amended on October 21, 2019, May 25, 2021, and December 23, 2022.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1018-fourtha.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 9, 2023 | | | | | | 10.18 | | | | | | | | | [removed: | | |]
| [removed: [10.10](https://www.sec.gov/Archives/edgar/data/1093557/000119312523149463/d446905dex101.htm)[*](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1019-2015emp.htm)] [added: 10.10*] | | | | | | [DexCom, Inc. Amended and Restated Severance and Change in Control Plan.](https://www.sec.gov/Archives/edgar/data/1093557/000119312523149463/d446905dex101.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | May 19, 2023 | | | | | | 10.1 | | | | | | | | | [removed: | | |]
| [removed: [10.11](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000174/dxcm6302023ex1006-firstame.htm)] [added: 10.11] | | | | | | [First Amendment to Second Amended and Restated Credit Agreement, dated June 1, 2023 by and between DexCom, Inc. and JPMorgan Chase Bank National Association.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000174/dxcm6302023ex1006-firstame.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | July 27, 2023 | | | | | | 10.06 | | | | | | | | | [removed: | | |]
| [removed: [10.12*](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex1012-2015emp.htm)] [added: 10.12*] | | | | | | [2015 Employee Stock Purchase Plan and forms of subscription agreements.](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex1012-2015emp.htm) | | | | | | [removed: | | |] [added: 10-K] | | | | | | [added: 000-51222] | | | | | | [added: February 8, 2024] | | | | | | [added: 10.12] | | | [removed: X] | | | | | |
| [removed: [10.13*](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex1013-amended.htm)] [added: 10.17*] | | | | | | [Amended and Restated 2015 Equity Incentive Plan and forms of award [removed: agreements.](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex1013-amended.htm)] [added: agreements.](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit1017.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | [removed: | | |]
| [removed: [10.14](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex1014-amended.htm)] [added: 10.13] | | | | | | [Amended and Restated Collaboration and License Agreement, dated November 20, 2018, by and between DexCom, Inc. and Verily Life Sciences LLC (formerly Google Life Sciences LLC).](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex1014-amended.htm) | | | | | | [removed: | | |] [added: 10-K] | | | | | | [added: 000-51222] | | | | | | [added: February 8, 2024] | | | | | | [added: 10.14] | | | [removed: X] | | | | | |
| [removed: [21.01](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex2101_12312023.htm)] [added: 21.1] | | | | | | [List of [removed: Subsidiaries.](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex2101_12312023.htm)] [added: Subsidiaries.](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit211.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | [removed: | | |]
| [removed: [23.01](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex2301_12312023.htm)] [added: 23.1] | | | | | | [Consent of Independent Registered Public Accounting [removed: Firm.](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex2301_12312023.htm)] [added: Firm.](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit231.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | [removed: | | |]
| [removed: 24.01] [added: 24.1] | | | | | | [removed: Power] [added: [Power] of Attorney (see signature page of this Form [removed: 10-K).] [added: 10-K).](#i6a987b433ae84cbfb2328647e6586107_223)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | [removed: | | |]
| [removed: [31.01](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023exhibit3101.htm)] [added: 31.1] | | | | | | [Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule [removed: 13a-14(a).](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023exhibit3101.htm)] [added: 13a-14(a).](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit311.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | [removed: | | |]
| [removed: [31.02](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023exhibit3102.htm)] [added: 31.2] | | | | | | [Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule [removed: 13a-14(a).](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023exhibit3102.htm)] [added: 13a-14(a).](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit312.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | [removed: | | |]
| [removed: [32.01*](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023exhibit3201.htm)] [added: 32.1*] | | | | | | [Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule [removed: 13a-14(b).](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023exhibit3201.htm)] [added: 13a-14(b).](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit321.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | [removed: | | |]
| [removed: [32.02*](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023exhibit3202.htm)] [added: 32.2*] | | | | | | [Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule [removed: 13a-14(b).](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023exhibit3202.htm)] [added: 13a-14(b).](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit322.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | [removed: | | |]
| [removed: [97.1*](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex971-compensa.htm)] [added: 97.1*] | | | | | | [Compensation Recovery Policy.](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex971-compensa.htm) | | | | | | [removed: | | |] [added: 10-K] | | | | | | [added: 000-51222] | | | | | | [added: February 8, 2024] | | | | | | [added: 97.1] | | | [removed: X] | | | | | |
| 101.INS | | | | | | Inline XBRL Instance Document | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | [removed: | | |]
| 101.SCH | | | | | | Inline XBRL Taxonomy Extension Schema Document | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | [removed: | | |]
| 101.CAL | | | | | | Inline XBRL Taxonomy Extension Calculation Linkbase Document | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | [removed: | | |]
| 101.DEF | | | | | | Inline XBRL Taxonomy Extension Definition Linkbase Document | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | [removed: | | |]
| 101.LAB | | | | | | Inline XBRL Taxonomy Extension Label Linkbase Document | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | [removed: | | |]
| 101.PRE | | | | | | Inline XBRL Taxonomy Extension Presentation Linkbase Document | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | [removed: | | |]
| 104 | | | | | | Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit 101) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | [removed: | | |]
| 10.14 | | | | | | [Warrant Termination Agreement between DexCom, Inc. and Bank of America, N.A., dated February 13, 2024.](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000024/dxcmexhibit101.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | February 15, 2024 | | | | | | 10.1 | | | | | | | | |
| 10.15* | | | | | | [Severance Agreement and General Release, dated October 22, 2024, between DexCom, Inc. and Teri Lawver.](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit1015.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | |
| 10.16 | | | | | | [Confidential Settlement and Patent License Agreement](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit1016.htm)[,](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit1016.htm) [dated December 20, 2024,](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit1016.htm) [](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit1016.htm)[between](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit1016.htm) [Abbott Diabetes Care Inc. and DexCom, Inc.](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit1016.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | |
| 19.1* | | | | | | [Insider Trading Policy.](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit191.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | |
| [19.1*](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex191-procedur.htm) | | | | | | [Procedures and Guidelines](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex191-procedur.htm) [](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex191-procedur.htm)[Governing](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex191-procedur.htm) [](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex191-procedur.htm)[Securities Trades by Company Personnel](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex191-procedur.htm)[.](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex191-procedur.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
Item 16. FORM 10-K SUMMARY
534 rewritten, 146 added, 108 removed, 672 unchanged
Read the full itemFY2024 item · filed February 18, 2025FY2023 item · filed February 8, 2024
| Dated: February [removed: 8, 2024] [added: 14, 2025] | | | | | | | | | | | | By: | | | | | | /s/ JEREME M. SYLVAIN | | |
| /s/ KEVIN R. SAYER | | | | | | Chairman of the Board of Directors, President and Chief Executive Officer (Principal Executive Officer) | | | | | | February [removed: 8, 2024] [added: 14, 2025] | | |
| /s/ JEREME M. SYLVAIN | | | | | | Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) | | | | | | February [removed: 8, 2024] [added: 14, 2025] | | |
| /s/ MARK G. FOLETTA | | | | | | Lead Independent Director | | | | | | February [removed: 8, 2024] [added: 14, 2025] | | |
| /s/ STEVEN R. ALTMAN | | | | | | Director | | | | | | February [removed: 8, 2024] [added: 14, 2025] | | |
| /s/ NICHOLAS AUGUSTINOS | | | | | | Director | | | | | | February [removed: 8, 2024] [added: 14, 2025] | | |
| /s/ RICHARD A. COLLINS | | | | | | Director | | | | | | February [removed: 8, 2024] [added: 14, 2025] | | |
| /s/ KAREN DAHUT | | | | | | Director | | | | | | February [removed: 8, 2024] [added: 14, 2025] | | |
| /s/ RIMMA DRISCOLL | | | | | | Director | | | | | | February [removed: 8, 2024] [added: 14, 2025] | | |
| /s/ BRIDGETTE P. HELLER | | | | | | Director | | | | | | February [removed: 8, 2024] [added: 14, 2025] | | |
| /s/ KYLE MALADY | | | | | | Director | | | | | | February [removed: 8, 2024] [added: 14, 2025] | | |
| /s/ ERIC J. TOPOL | | | | | | Director | | | | | | February [removed: 8, 2024] [added: 14, 2025] | | |
| [Report of Independent Registered Public Accounting [removed: Firm](#i70f957301cc34339a22f629982cd0734_181)] [added: Firm](#i6a987b433ae84cbfb2328647e6586107_229)] | | | [removed: F-[2](#i70f957301cc34339a22f629982cd0734_181)] [added: F-[2](#i6a987b433ae84cbfb2328647e6586107_229)] | | |
| [Consolidated Balance [removed: Sheets](#i70f957301cc34339a22f629982cd0734_184)] [added: Sheets](#i6a987b433ae84cbfb2328647e6586107_232)] | | | [removed: F-[4](#i70f957301cc34339a22f629982cd0734_184)] [added: F-[4](#i6a987b433ae84cbfb2328647e6586107_232)] | | |
| [Consolidated Statements of [removed: Operations](#i70f957301cc34339a22f629982cd0734_187)] [added: Operations](#i6a987b433ae84cbfb2328647e6586107_235)] | | | [removed: F-[5](#i70f957301cc34339a22f629982cd0734_187)] [added: F-[5](#i6a987b433ae84cbfb2328647e6586107_235)] | | |
| [Consolidated Statements of Comprehensive [removed: Income](#i70f957301cc34339a22f629982cd0734_190)] [added: Income](#i6a987b433ae84cbfb2328647e6586107_238)] | | | [removed: F-[6](#i70f957301cc34339a22f629982cd0734_190)] [added: F-[6](#i6a987b433ae84cbfb2328647e6586107_238)] | | |
| [Consolidated Statements of Stockholders’ [removed: Equity](#i70f957301cc34339a22f629982cd0734_193)] [added: Equity](#i6a987b433ae84cbfb2328647e6586107_241)] | | | [removed: F-[7](#i70f957301cc34339a22f629982cd0734_193)] [added: F-[7](#i6a987b433ae84cbfb2328647e6586107_241)] | | |
| [Consolidated Statements of Cash [removed: Flows](#i70f957301cc34339a22f629982cd0734_196)] [added: Flows](#i6a987b433ae84cbfb2328647e6586107_244)] | | | [removed: F-[8](#i70f957301cc34339a22f629982cd0734_196)] [added: F-[8](#i6a987b433ae84cbfb2328647e6586107_244)] | | |
| [Notes to Consolidated Financial [removed: Statements](#i70f957301cc34339a22f629982cd0734_199)] [added: Statements](#i6a987b433ae84cbfb2328647e6586107_247)] | | | [removed: F-[10](#i70f957301cc34339a22f629982cd0734_199)] [added: F-[10](#i6a987b433ae84cbfb2328647e6586107_247)] | | |
We have audited the accompanying consolidated balance sheets of DexCom, Inc. (the Company) as of December 31, [removed: 2023] [added: 2024] and [removed: 2022,] [added: 2023,] the related consolidated statements of operations, comprehensive income, stockholders’ equity and cash flows for each of the three years in the period ended December 31, [removed: 2023,] [added: 2024,] and the related notes and financial statement schedule listed in the Index at Item 15(a) (collectively referred to as the “consolidated financial statements”).
In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, [removed: 2023] [added: 2024] and [removed: 2022,] [added: 2023,] and the results of its operations and its cash flows for each of the three years in the period ended December 31, [removed: 2023,] [added: 2024,] in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, [removed: 2023,] [added: 2024,] based on criteria established in Internal [removed: Control-Integrated] [added: Control—Integrated] Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 [removed: framework)] [added: framework),] and our report dated February [removed: 8, 2024] [added: 14, 2025] expressed an unqualified opinion thereon.
The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or [removed: disclosures] [added: disclosure] to which it relates.
| [removed: 2023] | | | [added: 2024] | | | [removed: 2022] | | | [added: 2023] | | | [added: | | | 2022 | | |]
| *(In millions, except [added: share and] par value data)* | | | | | | | | | | | |
| Cash and cash equivalents | | | $ | [added: 606.1 | | | | | $ |] 566.3 | | | | | $ | 642.3 | |
| Short-term marketable securities | | | [removed: 2,157.8] [added: 1,973.3] | | | | | | [removed: 1,813.9] [added: 2,157.8] | | |
| Accounts receivable, net | | | [removed: 973.9] [added: 1,005.7] | | | | | | [removed: 713.3] [added: 973.9] | | |
| Inventory | | | [removed: 559.6] [added: 542.6] | | | | | | [removed: 306.7] [added: 559.6] | | |
| Prepaid and other current assets | | | [removed: 168.3] [added: 173.7] | | | | | | [removed: 192.6] [added: 168.3] | | |
| Total current assets | | | [removed: 4,425.9] [added: 4,301.4] | | | | | | [removed: 3,668.8] [added: 4,425.9] | | |
| Property and equipment, net | | | [removed: 1,113.1] [added: 1,339.9] | | | | | | [removed: 1,055.6] [added: 1,113.1] | | |
| Operating lease right-of-use assets | | | [removed: 71.4] [added: 62.8] | | | | | | [removed: 80.0] [added: 71.4] | | |
| Goodwill | | | [removed: 25.2] [added: 22.8] | | | | | | [removed: 25.7] [added: 25.2] | | |
| Intangibles, net | | | [removed: 134.5] [added: 103.4] | | | | | | [removed: 173.3] [added: 134.5] | | |
| Deferred tax assets | | | [removed: 419.4] [added: 481.2] | | | | | | [removed: 341.2] [added: 419.4] | | |
| Other assets | | | [removed: 75.0] [added: 173.0] | | | | | | [removed: 47.1] [added: 75.0] | | |
| Total assets | | | $ | [removed: 6,264.5] [added: 6,484.5] | | | | | $ | [removed: 5,391.7] [added: 6,264.5] | |
| Accounts payable and accrued liabilities | | | $ | [removed: 1,345.5] [added: 1,585.1] | | | | | $ | [removed: 901.8] [added: 1,345.5] | |
| Accrued payroll and related expenses | | | [removed: 171.0] [added: 112.0] | | | | | | [removed: 134.3] [added: 171.0] | | |
February 14, 2025
| 2024 | | | | | | 2023 | | | | | |
| Issuance of common stock in connection with achievement of sales-based milestone, net of issuance costs | | | | | | 1.5 | | | | | | — | | | | | | (188.1) | | | | | | | | | | | | | | | | | | — | | | | | | — | | | | | | 188.1 | | | | | | — | | |
| Purchases of treasury stock, including excise tax | | | | | | (10.4) | | | | | | — | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | — | | | | | | (749.5) | | | | | | (749.5) | | |
| Exercise and settlement of warrants | | | | | | 12.5 | | | | | | — | | | | | | (1,431.3) | | | | | | | | | | | | | | | | | | — | | | | | | — | | | | | | 1,431.3 | | | | | | — | | |
| Net income | | | | | | — | | | | | | — | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | 576.2 | | | | | | — | | | | | | 576.2 | | |
| Balance at December 31, 2024 | | | | | | 390.7 | | | | | | $ | 0.4 | | | | | $ | 2,093.8 | | | | | | | | | | | | | | | | | $ | (8.0) | | | | | $ | 1,597.6 | | | | | $ | (1,581.2) | | | | | $ | 2,102.6 | |
| Purchases of non-marketable equity securities | | | (81.3) | | | | | | (19.5) | | | | | | (14.5) | | |
| Other investing activities | | | (15.5) | | | | | | 1.9 | | | | | | 0.2 | | |
| December 31, 2024 | | | | | | | | | | | | | | |
| Dilutive potential securities: | | | | | | | | | | | | | | | | | | | | |
| RSUs and PSUs | | | | | | 0.7 | | | | | | 1.1 | | | | | | 1.0 | | |
| RSUs and PSUs | | | 1.3 | | | | | | — | | | | | | 0.4 | | |
We adopted ASU 2023-07 in the fourth quarter of 2024 on a retrospective basis, reflecting the application of the new standard in each prior reporting period.
In November 2024, the FASB issued ASU 2024-03, *Disaggregation of Income Statement Expenses*.
The ASU requires disaggregated disclosure of certain costs and expenses in the notes of the financial statements.
The ASU should be applied on a prospective basis although retrospective application is permitted.
Recent Securities and Exchange Commission Final Rules Not Yet Implemented
On March 6, 2024, the SEC adopted SEC Release Nos. 33-11275; 34-99678, The Enhancement and Standardization of Climate-Related Disclosures for Investors, to require the disclosure of certain climate-related information in registration statements and annual reports, including Scope 1 and 2 emissions and information about climate-related risks that have materially impacted, or are reasonably likely to have a material impact on, a company’s business strategy, results of operations, or financial condition.
In addition, under the final rules, certain disclosures related to severe weather events and other natural conditions will be required in audited financial statements.
The disclosure requirements would have begun phasing in for our reports and registration statements including financial information in the fiscal year ending December 31, 2025, however, in April 2024, the SEC issued an order staying the final rules until the completion of judicial review.
The SEC has since indicated that it intends to establish a new implementation period following the stay order.
We are currently evaluating the impact of this final rule on our disclosures.
In connection with the Restated Collaboration Agreement, we developed, launched and commercialized a CGM product in connection with the collaboration.
In the first quarter of 2024, we issued 1.5 million shares of our common stock in connection with our achievement of the second sales-based milestone.
We estimate the fair values of our Level 3 financial instruments based on unobservable inputs and other estimation techniques due to the absence of quoted market prices and inherent lack of liquidity.
| Cash equivalents | | | $ | 134.2 | | | | | $ | — | | | | | $ | — | | | | | $ | 134.2 | |
| Other long-term assets: | | | | | | | | | | | | | | | | | | | | | | | |
| Convertible notes receivable | | | — | | | | | | — | | | | | | 10.5 | | | | | | 10.5 | | |
(2) Includes assets which are primarily held pursuant to a deferred compensation plan for senior management, which consist mainly of mutual funds.
As we conduct business globally in many currencies, we are exposed to foreign exchange rate changes.
| | | | December 31, 2024 | | | | | | | | | | | | | | | | | | | | |
| U.S. government agencies (1) | | | $ | 1,149.4 | | | | | $ | 1.3 | | | | | $ | (0.6) | | | | | $ | 1,150.1 | |
| Commercial paper | | | 312.2 | | | | | | — | | | | | | (0.1) | | | | | | 312.1 | | |
| Corporate debt | | | 511.1 | | | | | | 0.4 | | | | | | (0.4) | | | | | | 511.1 | | |
(1) Includes debt obligations issued by U.S. government-sponsored enterprises or U.S. government agencies.
(1) Includes debt obligations issued by U.S. government-sponsored enterprises or U.S. government agencies.
| | | | | | | | | | | | | December 31, 2024 | | | | | | | | | | | | | | |
| Verily intangible asset (1) | | | | | | 3.3 | | | | | | $ | 152.4 | | | | | $ | (59.5) | | | | | $ | 92.9 | |
| Customer relationships | | | | | | 1.8 | | | | | | 17.5 | | | | | | (13.0) | | | | | | 4.5 | | |
| /s/ BARBARA E. KAHN | | | | | | Director | | | | | | February 8, 2024 | | |
| Barbara E. Kahn | | | | | | | | | | | | | | |
February 8, 2024
| Collaborative research and development fee | | | — | | | | | | — | | | | | | 87.1 | | |
| Balance at December 31, 2020 | | | | | | 384.4 | | | | | | 0.4 | | | | | | 1,726.5 | | | | | | 3.2 | | | | | | (78.2) | | | | | | (100.0) | | | | | | 1,551.9 | | |
| Conversions of 2023 Notes | | | | | | 1.4 | | | | | | — | | | | | | 32.6 | | | | | | — | | | | | | — | | | | | | 24.6 | | | | | | 57.2 | | |
| Collaborative research and development fee | | | | | | — | | | | | | — | | | | | | 87.1 | | | | | | — | | | | | | — | | | | | | — | | | | | | 87.1 | | |
| Tax benefit related to Senior Convertible Notes | | | | | | — | | | | | | — | | | | | | (4.4) | | | | | | — | | | | | | — | | | | | | — | | | | | | (4.4) | | |
| Benefit of note hedge upon conversions of 2023 Notes | | | | | | (12.2) | | | | | | — | | | | | | 1,496.5 | | | | | | — | | | | | | — | | | | | | (1,490.3) | | | | | | 6.2 | | |
| Collaborative research and development fee | | | — | | | | | | — | | | | | | 87.1 | | |
| Loss on extinguishment of debt | | | — | | | | | | — | | | | | | 0.1 | | |
| Realized (gain) loss on equity investment | | | (1.9) | | | | | | (0.2) | | | | | | (11.6) | | |
| Other investing activities | | | (17.6) | | | | | | (14.3) | | | | | | 10.1 | | |
*Consideration Payable to the Customer*
We pay administrative and service fees to certain of our distributors based on a fixed percentage of the product price.
These fees are not in exchange for a distinct good or service and therefore are recognized as a reduction of the transaction price.
We accrue for these fees based on actual net sales and contractual fee rates negotiated with the customer.
We generally provide a “30-day money back guarantee” program whereby first-time end-user customers may return Reusable Hardware.
*Various Other Promotional or Incentive Arrangements*
Other promotional or incentive arrangements are periodically offered to customers, including but not limited to co-payment assistance we provide to patients with commercial insurance, promotional programs related to the launch of products or other targeted promotions.
We record a provision for the incentive earned based on the number of estimated claims and our estimate of the cost per claim related to product sales that we have recognized as revenue.
In cases where our free-of-charge software, mobile applications and updates are deemed to be separate performance obligations, revenue is recognized over time on a ratable basis over the estimated life of the related Reusable Hardware component.
Our sales of Components include an assurance-type warranty.
Revenue recognized in the period from performance obligations satisfied in previous periods was not material for the periods presented.
Deferred cost of sales are associated with transactions for which revenue recognition criteria are not met but product has shipped and released from inventory.
| Product Shipment Costs | | | | | | | | | | | | | | |
We record the amounts we charge our customers for the shipping and handling of our products in revenue and we record the related costs as cost of sales in our consolidated statements of operations.
| Dilutive potential common stock outstanding: | | | | | | | | | | | | | | | | | | | | |
| Restricted stock units and performance stock units | | | | | | 1.1 | | | | | | 1.0 | | | | | | 2.1 | | |
| Restricted stock units and performance stock units | | | — | | | | | | 0.4 | | | | | | — | | |
In October 2021, the FASB issued ASU No. 2021-08, *Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.* This guidance is intended improve the accounting for acquired revenue contracts with customers in a business combination.
The new guidance requires that the acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606.
The amendments should be applied prospectively to business combinations occurring on or after the adoption date.
We adopted ASU 2021-08 in the first quarter of 2023 and there was no impact to our consolidated financial statements.
All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment.
The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted.
The Restated Collaboration Agreement requires us to use commercially reasonable efforts to develop, launch and commercialize the CGM product(s) that are the subject of the collaboration according to certain timing and other objectives, and provides for one executive sponsor from each of Dexcom and Verily to meet periodically and make decisions related to the collaboration (within a limited scope of authority) by consensus.
If we elect to make these milestone payments in cash, any such cash payment would be equal to the number of shares that would otherwise be issued for the given milestone payment multiplied by the value of our stock on the date the relevant milestone is achieved, and adjusted to give effect to any stock splits, dividends, or similar events.
We intend to pay the remaining sales-based contingent milestone in shares of our common stock.
Upon achievement of the first sales-based milestone event and payment of the corresponding milestone fee by us in December 2023, the term of the Restated Collaboration Agreement was extended from December 31, 2028 to December 31, 2033.
An excerpt. Shown here: 40 of 534 rewritten, 40 of 146 added and 40 of 108 removed. The counts are complete. For every sentence, read Item 16. FORM 10-K SUMMARY in the FY2024 filing and the FY2023 filing.